



المجلس الصحي السعودي
Saudi Health Council

KINGDOM OF SAUDI ARABIA
SAUDI HEALTH COUNCIL
NATIONAL CANCER CENTER
SAUDI CANCER REGISTRY

**CANCER INCIDENCE
REPORT
SAUDI ARABIA**

2022



المجلس الطبي السعودي
Saudi Health Council



KINGDOM OF SAUDI ARABIA
SAUDI HEALTH COUNCIL
NATIONAL CANCER CENTER
SAUDI CANCER REGISTRY



CANCER INCIDENCE
REPORT
SAUDI ARABIA
2022



In the Name of Allah, the Most Gracious, the Most Merciful

The National Cancer Center (NCC) of the Saudi Health Council, presents the annual Cancer Registry report of the year 2022 that outlines the recent achievements of the registry head office, its activities and programs. The Saudi Cancer Registry (SCR) reports support the efforts made in the fight against cancer, and provide those in-charge of cancer healthcare and educational projects with the accurate cancer information that reflect the situational analysis of cancer in Saudi Arabia. This data represents the actual situation of cancer cases in the Kingdom and identifies the most common types based on gender, age, and geographical location.

The reports of the registry allow decision-makers to plan the development of cancer healthcare and health promotion programs to control cancer, aligned with the national strategies and healthcare objectives. Inspired by Vision 2030 to achieve the goals of the ambitious leadership, and the expectations of beneficiaries, healthcare coordination and integration is the prime goal of the Saudi Health Council that strengthen healthcare provision.

In conclusion, the witnessed progress in our beloved country's healthcare sector is a blessing from Allah the Almighty and then, the result of the support of the ambitious leadership of the Custodian of the Two Holy Mosques, and the Royal Highness, the Crown Prince, May Allah protect them, and the close follow-up by his Excellency the Chairman, and the members of the Saudi Health Council. I would like to express my sincere gratitude to my colleagues at the Saudi Health Council, represented by National Cancer Center (NCC), for their diligent work and continuous efforts in preparing this report and achieving the mission and objectives of the Saudi Cancer Registry. I would also like to extend my appreciations to all healthcare staff, organizations, institutions, and charity that involved in healthcare provision and raising awareness to alleviate cancer burden in Saudi Arabia.

Dr. Nahar M. Al-Azemi
Secretary General of
the Saudi Health Council



Praise be to Allah, the Lord of the Worlds, and blessings and peace be upon His prophet and messenger Mohammad.

National Cancer Center (NCC) at the Saudi Health Council plays important roles in collecting, compiling and analyzing data on the new cancer cases in the Kingdom of Saudi Arabia for the year 2022 and ensuring their validity, this is the result of the participation of all government and private health sectors in the Kingdom in cancer data collection.

National Cancer Center (NCC) is consistently following up on the Registry's in providing administrative and technical assistance and utilizing the accumulated statistics to establish cancer control and treatment priorities in Saudi Arabia, Moreover, National Cancer Center (NCC) is committed in developing suitable national programs to enhance the levels of healthcare provided to cancer patients. The Saudi Cancer Registry, which was established in 1992 AD, was one of the first national registers in the Kingdom

I am pleased to thank the technical team responsible for preparing and implementing this report, our National Cancer Center (NCC) colleagues and cancer registrars in all health sectors for their efforts in accomplishing this great work. We extend our gratitude to the members of the Scientific Committee and the reviewers of this report for their dedicated efforts towards the Saudi Cancer Registry, aimed at serving the health sector and benefiting both citizens and residents.

Professor Mushabbab Ali Al-Asiri

General Director of The National
Cancer Center, Saudi Health Council

PREPARED BY

| Mr. Ahmed Al-Rawaji.

Saudi Cancer Registry Supervisor at The Saudi Arabia Cancer Center, Saudi Health Council.

| Mr. Akram Al-Zamzami

Health Data Analyst and Quality Specialist at The Saudi Arabia Cancer Center, Saudi Health Council.

| Mr. Ahmed Al-nemari

Health Data Analyst and Quality Specialist at The Saudi Arabia Cancer Center, Saudi Health Council.

| Mr. Zeyad Al-Shahrani

Health Data Analyst and Quality Specialist at The Saudi Arabia Cancer center, Saudi Health Council.

| Mr. Saleh Al-Alyani

Health Data Analyst and Quality Specialist at The Saudi Arabia Cancer Center, Saudi Health Council.

REVIEWED BY

| Prof. Mushabbab Ali Al-Asiri

General Director Of The Saudi Arabia National Cancer Center, Saudi Health Council.

| Dr. Ali Al-Zahrani

Principal Clinical Scientist / Senior Consultant, Executive Director, Gulf Center for Cancer Control & Prevention, King Faisal Specialist Hospital & Research Center.

| Mrs. Adhwaa Al-Juhani

General Director Assistant Of The Saudi Arabia National Cancer Center, Saudi Health Council.



INTRODUCTION.

This is the Twenty-fifth cancer incidence report published by the Saudi Cancer Registry. Previous publications included the Incidence Reports for the years: 1994-1996, 1997-1998, 1999-2000, and yearly reports until 2022.

This report provides statistics on cancer incidence that can be used for better planning and effective measurement of early detection and management of cancer.

THE STRUCTURE OF THIS REPORT CAN BE OUTLINED AS FOLLOWS:

PART I- MATERIALS AND METHODS.

This part of the report contains information about the background and methods of the Saudi Cancer Registry used in collecting and analyzing the data. We present the basics of coding and classification of tumor topography, morphology, and extent of disease at the time of diagnosis. Also, we describe the software programs we have used to analyze the data.

PART II- OVERVIEW OF CANCER INCIDENCE.

Part II presents the overall cancer incidence in Saudi Arabia diagnosed between 01 January and 31 December 2022. Figures, tables, and line/bar charts are used to present cancer distribution by gender and age groups. Morphology distributions for

the most common cancers are also presented in tables. In addition, incidence tables are used to present the total Number of Cases, Age-Standardized Incidence Rate (ASR), Crude Incidence Rate (CIR), and Cumulative Rates (per 100,000 population) by gender for each primary cancer site. Separate bar charts are used to demonstrate the distribution of the most common cancers by gender in each of the 13 administrative regions of Saudi Arabia.

PART III- CANCER INCIDENCE FOR THE MOST COMMON SITES 2022.

In this part, the incidence of the most common cancers reported among Saudi males and females is outlined. For each cancer site, the total number and proportions of all newly diagnosed cases, the ASR, and the corresponding cancer ranking for each gender are also presented. In addition, ASR for the most common cancers among Saudis is compared with the ASR reported from selected developed and developing countries.

PART IV-CANCER INCIDENCE AMONG NON-SAUDIS.

This part presents numbers of cancer cases among the Non-Saudis including the most common types of cancer. The analysis of the Non-Saudis is performed separately due to the nature of the expatriate population in which a large proportion is aged between 25 and 44, especially among males.

PART V- INCIDENCE TABLES.

This part contains the following detailed tables for all newly diagnosed cancer types for the Saudis and the non-Saudis diagnosed in 2022.

- Distribution of cancer cases among Saudis by age group and gender.
- Distribution of cancer cases among non-Saudis by age group and gender.
- Cancer Incidence (per 100,000 population) among Saudis by age group and gender.
- Cancer Incidence (per 100,000 population) among non-Saudis by age group and gender.
- Age-standardized incidence rate and relative frequencies among Saudis by cancer site, gender.

PART VI- ARABIC SUMMARY.

It is enclosed an Arabic summary of Cancer Statistics in Saudi Arabia for the Year 2022.

TABLE
OF CONTENTS

TABLE OF CONTENTS

Introduction	04	Corpus Uteri Cancer (C54)	45
		Kidney (C64)	47
PART I		PART IV	
MATERIALS AND METHODS	10	CANCER AMONG NON-SAUDI 2022	50
Background on Saudi Arabia	11	Cancer Incidence Among Non-Saudi	51
Saudi Cancer Registry	11		
Definitions of Statistical Terms	13	PART V	
		INCIDENCE TABLES	54
PART II		Table 5.1.1: NNumber of Cases Among Saudi	
OVERVIEW OF CANCER INCIDENCE, 2022	16	Males by Primary Site and Age Groups, 2022	55
Cancer Incidence in Saudi Arabia, 2022	17	Table 5.1.2: Number of Cases Among Saudi	
Cancer Distribution Among Saudi Nationals,		Females by Primary Site and Age Groups, 2022	56
2022	18	Table 5.1.3: Age-Specific Incidence Rate	
Cancer Incidence Among Adults		(AIR), Age Standardized Incidence Rate	
(> 14 Years), 2022	23	(ASR) Among Saudi Males (per 100,000) by	
Childhood Cancer Reported to Saudi Cancer		Primary Site and Age groups, 2022	57
Registry (≤ 14 Years), 2022	24	Table 5.1.4: Age-Specific Incidence Rate	
International Comparison of Age-Standardized		(AIR), Age Standardized Incidence Rate	
Incidence Rates	27	(ASR) Among Saudi Females (per 100,000)	
		by Primary Site and Age groups, 2022	58
PART III		Table 5.4.1: umber of Cases Among	
CANCERS INCIDENCE FOR THE MOST		Non-Saudi Males by Primary Site and Age	
COMMON SITES, 2022	28	Groups, 2022	59
Cancer Incidence for the Most Common Sites,		Table 5.4.2: Number of Cases Among	
2022	29	Non-Saudi Females by Primary Site and	
Female Breast Cancer (C50)	30	Age Groups, 2022	60
Colorectal Cancer (C18-C20)	31		
Thyroid Cancer (C73)	33		
Non-Hodgkin Lymphoma (C82-C85; C96)	35		
Leukaemia (C91-C95)	37		
Prostate Cancer (C61).....	49		
Liver Cancer (C22)	41		
Brain, Central nervous system (C70-C72)	43		

TABLE OF CONTENTS

Table 5.4.3: Age-Specific Incidence Rate (AIR), Age Standardized Incidence Rate (ASR) Among Non-Saudi Males (per 100,000) by Primary Site and Age groups, 2022.	61
Table 5.4.4: Age-Specific Incidence Rate (AIR), Age Standardized Incidence Rate (ASR) Among Non-Saudi Females (per 100,000) by Primary Site and Age groups, 2022	62
Acknowledgment	63
Arabic Summary	66

PART I

MATERIALS AND METHODS



BACKGROUND ON SAUDI ARABIA

Saudi Arabia is a vast country extending over four-fifths of the Arabian Peninsula. It stretches from the Arabian Gulf in the east to the Red Sea in the west. It is approximately 2,149,700* square kilometers divided into 13 administrative regions Figure 1.1.



Figure 1.1: Administrative regions of Saudi Arabia.

The estimated population of Saudi Arabia in 2022 was 32175224. Saudi nationals were estimated to be 18792262 of these 9434131 (50.2%) were males and 9358131 (49.8%) were females.

The non-Saudi population was 13382962 of these 10244464 (76.5%) were males and 3138498 (23.5%) were females. Figures 1.2 and 1.3 show the Saudi and Non-Saudi population pyramids by gender and age group respectively.

Figure 1.2: Population pyramid of Saudis (%) by gender and age group, 2022.





Figure 1.3: Population pyramid of non-Saudis (%) by gender and age group, 2022.



Saudi cancer registry.

National cancer registries are the cornerstone of national cancer control and prevention programs; to achieve the accurate knowledge of the numbers and rates of cancer cases and associated deaths, in addition to the knowledge of the geographical distribution of cancer cases, prediction of the financial and social burden of cancer-related health care activities , monitoring the results of risk factors associated with cancer (food, carcinogens and behaviors), monitoring the performance of preventive and therapeutic programs, analyzing the obstacles facing these programs, directing the local product of financial and human resources and investments, and supporting community health research and clinical studies.

The Saudi Cancer Registry is one of the first national registries in the Kingdom of Saudi Arabia, if not the first, as it was established in 1412 AH / 1992 AD. The statistical information provided by the Saudi Cancer Registry has been extremely important for developing cancer preventive and treatment services in the Kingdom over the past thirty years.

Reports have been published annually since 1994 to date. The reports are circulated as a tool to assist in making national decisions regarding cancer health services and the optimal distribution of resources. These reports are viewed by the national bodies to develop and maintain cancer care in different regions in Saudi Arabia while the for the international agencies for measuring the global burden of cancer.

Cancer data are also provided if requested to various public and private sectors and to many researchers in the fields of cancer sciences.

The Saudi Cancer Registry collects data through oncology centers cancer registrars, most of all cancer cases are registered and their data is entered using a certified software. Data is processed and quality is managed, reviewed, and analyzed to generate the annual Saudi Cancer Registry reports.

Organizational structure.

The committee provides scientific guidance to SCR, reviews cancer statistics reports, data requests, and provides help in disseminating reliable information; in addition to ensuring data confidentiality according to national and international guidelines.

Regional Offices.

all regions. Quality control processes include verification of site, morphology, staging information, case linkage (tumor and patient), and consolidation of data. The Main Office also prepares annual reports for dissemination to the medical community, government departments, international organizations and the public.

Data management.

A royal decree has categorized cancer as a mandatory notifiable disease. This ensures the opportunity for comprehensive data collection. The SCR strives for full access to cancer data from all governmental and private hospitals, clinics, and laboratories throughout the Kingdom.

Cancer data are abstracted from patients' medical records based on clinical and/or histopathological diagnosis by SCR trained cancer registrars. Abstracted data includes personal identifications (name, ID number, gender, age), demographic information (address, telephone number, nationality), and tumor details (diagnosis date, primary site, histology, behavior, grade, stage, basis of diagnosis). The primary site (topography) and histology (morphology) of the malignancies are identified and coded according to the International Classification of Diseases for Oncology 3rd Edition (ICD-O-3), published by the World Health Organization (WHO), 2000. Starting from the year 2001, changes were made in the coding of cancer types and behaviors as well as staging according to SEER Summary Stage manual 2000 to increase accuracy and consistency in stage coding. SEER Summary Stage Manual 2000 is available on the web (can get the link here).

While there have not been any changes in the primary site codes, there are significant changes regarding histology (cell types). Leukaemia and lymphoma are particularly affected. Some cases that were previously considered benign are now counted as malignant. Also, a small number of cancers that were.

Notification.

This report covers data that were diagnosed between January and December 2022. Incident cases identified after this date (late reporting) will be reported in subsequent incidence reports. It is anticipated that the number of late-reported cases will decrease as the case ascertainment processes have improved during the past years. Our aim is to reduce reporting gap between the year of diagnosis and the year of publishing the incidence report to a maximum of 2 years while maintaining high quality and completeness of data.

Definitions of Statistical Terms

Age-Specific Incidence Rate (AIR).

The number of cancer cases occurring during a specific period in a population of a specific age and gender group, divided by the number of mid-year population of that age and gender group.

Age-Standardized Rate (ASR).

The age-standardized rate is a summary measure of the rate that a population would have if it had a standard age structure. Standardization is necessary when comparing several populations that differ with respect to age structure. The most frequently used standard population is the World Standard Population (see below). The calculated incidence is known as the World Standardized Incidence Rate. The rate is expressed per 100,000 population.

World Standard Population.

Age Class	Age Class
0 - 4	12.000
5 - 9	10.000
10 -14	9.000
15 -19	9.000
20 - 24	8.000
25 - 29	8.000
30 - 34	6.000
35 - 39	6.000
40 - 44	6.000
45 - 49	6.000
50 - 54	5.000
55 - 59	4.000
60 - 64	4.000
66 - 69	3.000
70 - 74	2.000
75 +	2.000
Total	100.000

*Doll R. Payne P. Waterhouse J. Cancer Incidence in Five Continents Vol. I. International Union against Cancer. 1966

Crude Incidence Rate (CIR).

The crude incidence rate for a cancer site is the total number of cases registered as a proportion of the total population. It denotes the approximate number of cases occurring in every 100,000 individuals. All rates are thus, expressed as per 100,000 population. Cancer rates vary greatly with age and the crude rate is strongly influenced by the demographic structure of the population. Hence, if the population structure changes over time the crude rate over that period may be artificially altered. It is not appropriate to compare crude rates across geographical areas of cancer registries with different population age structures. Therefore, in order to assess time trends in registration data or compare incidence across geographical areas or between registries, it is necessary to first standardize the rates with respect to age.

Cumulative incidence rate.

The cumulative incidence rate is the probability or risk of individuals developing the disease during a specified period. For cancer, it is expressed as the number of newborn children (out of 100, or 1000) who would be expected to develop a particular cancer type before the age of 65 (or 70, or 75) if they had the rates of cancers currently observed. Like the age-standardized rate, it permits comparison between populations of different age structures. In this report, the age ranges between 0 to 64 and 0 to 74 are used. The cumulative rate is the summation of the cancer age-specific rates, which are computed for five-year age intervals.

ICD-10.

The World Health Organization's International Classification of Diseases, tenth edition.

ICD-O-3.

The World Health Organization's International Classification of Diseases for Oncology, 3rd Edition has been the standard coding system for neoplasms for over 25 years. The coding system includes a four-character code for the primary site, a four-digit numeric code for cell type, a one-digit code for behavior, and a one-digit code for tumor aggressiveness (grade).

Incidence rate.

An incidence rate is defined as the rate at which a new event occurs in a population. It is calculated as the number of new cases of disease arising in a population over a defined period, divided by the population at risk of developing that disease.

Mean.

The simple mathematical average of two or more numbers.

Median.

The midpoint of the range numbers that are arranged in order of value.

Metastasis.

Metastasis is the distant spread of cancer from its original site to other organs of the body, including lymph nodes, skeletal, and or visceral organs.

Range.

It is the difference between the maximum and minimum values in a set of observations.

Rank.

This measure reflects the importance of a specific cancer site relative to other sites, in terms of the number of registrations. Ranking illustrates the most and least frequent cancer sites in a population according to their frequency.

Ratio.

It is the relation between two quantities. The first quantity is a numerator and the second is a denominator.

Relative frequency.

This statistic is defined as the number of specific cancer cases registered relative to the total number of all cancer. It is expressed as a percentage.

Summary Stage.

Staging is the grouping of cancer cases into broad categories based on the extent of the disease.



PART II

OVERVIEW OF CANCER INCIDENCE 2022



Cancer incidence in Saudi Arabia, 2022

Between January 01 and December 31, 2022, the total number of newly diagnosed cancer cases reported to the Saudi Cancer Registry (SCR) was 24470. Overall cancer was more among women than men; it affected 11256 (46%) males and 13214 (54%) females. A total of 19419 cases were reported among Saudi nationals, 4849 among non-Saudis, and 202 of unknown nationalities.

A total of 24072 cases were analyzed, of which 19233 (79.9%) were Saudi nationals and 4839 (20.1%) were non-Saudis.

A total of 398 cases were excluded from the analysis: 202 cases of them were unknown nationalities, and 196 cases failed to be converted to ICD-10 codes. The software (CanReg-4) does not include in situ cases in the statistical analysis, **Table 2.1**.

Among Saudis 8748 (45.4%) were males and 10485 (54.6%) were females with a male to female ratio of 100 to 119.9. The crude incidence rates (CIR) of all cancers were 92.8/100,000 in males and 112.1/100,000 in females.


The overall age-standardized incidence rate (ASR) was 144.9/100,000 in males and 159.1/100,000 in females.

Table 2.1: Distribution of analyzed and non-analyzed cancer cases reported to Saudi Cancer Registry by nationality and gender, 2022.

Saudis						Unknown Nationality			Non-Saudis					
Analyzed			Non Analyzed						Analyzed			Non Analyzed		
Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
8748	10485	19233	94	92	186	94	108	202	2316	2523	4839	4	6	10

The age-specific incidence rate (AIR) increased with advancing age in both genders. The median age at diagnosis was 57 with a range of 0-104 for males, and 53 with a range of 0-109 for females, **Figure 2.2**.

Figure 2.2: Age-Specific Incidence Rate (AIR) for all cancer among Saudis, 2022.



Confirmation of malignancy was based mainly on histopathology reports (92.1%), followed by Cytology and Hematological (2.9%), then Histology of metastases (2.4%), then Medical Imaging (1.3%). Other sources such as Clinical and Death Certificate were the source that is about 0.4%, **Table 2.3.**

Table 2.3: Basis of diagnosis of cancer cases, 2022.

Basis of Diagnosis	No	%
Histology of primary	17720	92.1
Cytology/Haematological	557	2.9
Histology of metastases	466	2.4
Medical Imaging	248	1.3
Unknown	154	0.8
Clinical	66	0.3
Surgery	10	0.1
DCO (Death Certificate Only)	8	0.0
Laboratory test	4	0.0
Total	19233	100.0

Cancer Distribution among Saudi Nationals, 2022.

In females, the highest number of cancer cases was reported for the age group (45-59), with a total of 3472 (33.1%) cancer cases. Whereas, in males, the highest number of cases was reported for the age group (60-74), with a total of 2738 (31.3%) cancer cases, **Figure 2.3.**

Figure 2.3: Distribution of cancer cases among Saudi nationals by gender and age groups, 2022.





Figure 2.4: Distributions of the most frequent types of cancer among Saudi nationals by gender and age groups, 2022.








Table 2.4: Most common cancers among Saudi nationals, 2022.

Sites	No.	%
Breast	3334	17.3
Colorectal	2535	13.2
Thyroid	1677	8.7
NHL	1098	5.7
Leukaemia	892	4.6
Prostate	661	3.4
Liver	650	3.4
Brain, CNS	650	3.4
Corpus Uteri	647	3.4
Kidney	630	3.3

Table 2.5: Most common cancers among Saudi nationals by sex, 2022.

Male			Female		
	8748	%		10485	%
Colorectal	1470	16.8	Breast	3280	31.3
Prostate	661	7.6	Thyroid	1288	12.3
NHL	627	7.2	Colorectal	1065	10.2
Leukaemia	517	5.9	Corpus Uteri	647	6.2
Bladder	474	5.4	NHL	471	4.5
Lung	464	5.3	Leukaemia	375	3.6
Liver	437	5.0	Ovary	300	2.9
Kidney	405	4.6	Brain, CNS	283	2.7
Thyroid	389	4.4	Kidney	225	2.1
Brain, CNS	367	4.2	Liver	213	2.0

Table 2.6: Number, percentage, CIR, ASR, and cumulative rates (per 100,000) among Saudi nationals by primary cancer site and gender, 2022.

ICD-10	Site	Male						Female					
		No.	%	Crude Rate	ASR World	Cumulative Rate		No.	%	Crude Rate	ASR World	Cumulative Rate	
						0 - 64	0 - 74					0 - 64	0 - 74
All	All sites Total	8748	%100.00	92.8	144.9	281.8	369.9	10485	%100.00	112.1	159.1	395.7	474.25
Not C44	All sites but C44	8495	%97.10	90.1	140.5	276	361.6	10334	%98.60	110.5	156.6	392.3	469
C00	Lip	13	%0.10	0.1	0.2	0.25	0.5	12	%0.10	0.1	0.2	0.20	0.35
C01-C02	Tongue	78	%0.90	0.8	1.4	2.50	3.45	65	%0.60	0.7	1	2.45	2.75
C03-C06	Mouth	66	%0.80	0.7	1.2	1.45	2.50	59	%0.60	0.6	1	1.80	2.45
C07-C08	Salivary glands	28	%0.30	0.3	0.5	0.95	1.25	20	%0.20	0.2	0.2	0.95	0.95
C09	Tonsil	7	%0.10	0.1	0.1	0.20	0.35	2	%0.00	0	0	0.05	0.10
C10	Other Oropharynx	6	%0.10	0.1	0.1	0.15	0.30	3	%0.00	0	0	0.05	0.05
C11	Nasopharynx	198	%2.30	2.1	3	8.25	9.40	51	%0.50	0.5	0.8	2.20	2.50
C12-C13	Hypopharynx	12	%0.10	0.1	0.2	0.30	0.40	8	%0.10	0.1	0.1	0.35	0.40
C14	Pharynx unspec.	2	%0.00	0	0	0.05	0.10	3	%0.00	0	0.1	0.00	0.05
C15	Oesophagus	102	%1.20	1.1	1.9	2.65	3.70	50	%0.50	0.5	0.8	1.50	1.95
C16	Stomach	230	%2.60	2.4	4.1	6.60	8.80	137	%1.30	1.5	2.2	4.40	5.80
C17	Small intestine	68	%0.80	0.7	1.1	2.20	2.85	52	%0.50	0.6	0.8	1.85	2.05
C18	Colon	895	%10.20	9.5	16.1	26.10	37.45	741	%7.10	7.9	12.4	24.25	32.05
C19-C20	Rectum	575	%6.60	6.1	10.1	19.35	25.30	324	%3.10	3.5	5.4	10.95	13.80
C21	Anus	22	%0.30	0.2	0.4	0.70	1.00	11	%0.10	0.1	0.2	0.35	0.45
C22	Liver	437	%5.00	4.6	8.5	8.80	15.90	213	%2.00	2.3	3.9	4.90	8.30
C23-C24	Gallbladder etc.	104	%1.20	1.1	2	2.60	4.40	110	%1.00	1.2	2	2.65	4.25
C25	Pancreas	290	%3.30	3.1	5.5	8.25	12.15	189	%1.80	2	3.3	5.35	7.80
C30-C31	Nose, sinuses etc.	21	%0.20	0.2	0.3	0.65	0.80	6	%0.10	0.1	0.1	0.15	0.25
C32	Larynx	108	%1.20	1.1	2.1	2.50	4.30	8	%0.10	0.1	0.1	0.20	0.25
C33-C34	Trachea,Bronchus,Lung	464	%5.30	4.9	8.8	12.15	19.10	159	%1.50	1.7	2.7	4.90	6.60
C37-C38	Other Thoracic organs	38	%0.40	0.4	0.5	1.45	1.65	26	%0.20	0.3	0.3	1.15	1.30
C40-C41	Bone	115	%1.30	1.2	1.3	5.30	5.55	108	%1.00	1.2	1.2	4.90	5.20
C43	Melanoma of Skin	17	%0.20	0.2	0.3	0.45	0.60	16	%0.20	0.2	0.3	0.45	0.70
C44	Other Skin	253	%2.90	2.7	4.3	5.80	8.30	151	%1.40	1.6	2.6	3.40	5.25
C45	Mesothelioma	7	%0.10	0.1	0.1	0.20	0.25	3	%0.00	0	0	0.10	0.10
C46	Kaposi sarcoma	36	%0.40	0.4	0.6	0.95	1.25	6	%0.10	0.1	0.1	0.10	0.15
C47;C49	Connective,Soft tissue	137	%1.60	1.5	1.9	5.75	6.45	113	%1.10	1.2	1.5	4.60	5.00
C50	Breast	54	%0.60	0.6	0.9	1.65	2.10	3280	%31.30	35.1	49.7	132.75	152.85
C51	Vulva	-	-	-	-	-	-	14	%0.10	0.1	0.2	0.55	0.65
C52	Vagina	-	-	-	-	-	-	13	%0.10	0.1	0.2	0.45	0.55
C53	Cervix Uteri	-	-	-	-	-	-	157	%1.50	1.7	2.4	5.70	7.15
C54	Corpus Uteri	-	-	-	-	-	-	647	%6.20	6.9	11.6	20.15	28.95
C55	Uterus unspec.	-	-	-	-	-	-	160	%1.50	1.7	2.9	5.00	7.30
C56	Ovary	-	-	-	-	-	-	300	%2.90	3.2	4.3	12.20	14.10
C57	Other Female Genital	-	-	-	-	-	-	31	%0.30	0.3	0.5	1.05	1.35
C58	Placenta	-	-	-	-	-	-	0	%0.00	0	0	0.00	0.00
C60	Penis	2	0	0	0	0	0.05	-	-	-	-	-	-
C61	Prostate	661	0.076	7	13.4	9.3	21.95	-	-	-	-	-	-
C62	Testis	214	0.024	2.3	2	10.65	10.65	-	-	-	-	-	-
C63	Other male genital	4	0	0	0.1	0.2	0.2	-	-	-	-	-	-
C64	Kidney	405	0.046	4.3	6.7	15.05	18.5	225	%2.10	2.4	3.3	8.45	10.25
C65	Renal Pelvis	9	0.001	0.1	0.1	0.35	0.4	6	%0.10	0.1	0.1	0.15	0.25
C66	Ureter	7	0.001	0.1	0.1	0.1	0.25	6	0.001	0.1	0.1	0.15	0.25
C67	Bladder	474	0.054	5	8.9	11.4	18	88	0.008	0.9	1.4	2.25	3.05
C68	Other Urinary organs	5	%0.10	0.1	0.1	0.15	0.20	2	0	0	0	0.10	0.1
C69	Eye	28	%0.30	0.3	0.4	0.95	1.10	18	0.002	0.2	0.2	0.80	0.8
C70-C72	Brain, Nervous system	367	%4.20	3.9	4.9	16.05	17.35	283	%2.70	3	3.7	12.10	13.45
C73	Thyroid	389	%4.40	4.1	5.4	17.15	18.75	1288	%12.30	13.8	16.5	58.85	62.70
C74	Adrenal gland	24	%0.30	0.3	0.3	1.05	1.10	27	%0.30	0.3	0.3	1.25	1.30
C75	Other Endocrine	17	%0.20	0.2	0.2	0.75	0.85	9	%0.10	0.1	0.1	0.35	0.35
C81	Hodgkin disease	360	%4.10	3.8	4	17.05	17.45	200	%1.90	2.1	2.3	8.85	9.45
C82-C85;C96	Non-Hodgkin lymphoma	627	%7.20	6.7	9.5	23.05	27.95	471	%4.50	5	7.1	16.20	20.15
C88	Immunoproliferative dis.	0	%0.00	0	0	0.00	0	1	%0.00	0	0	0.05	0.05
C90	Multiple Myeloma	127	%1.50	1.3	2.3	3.80	5.3	85	%0.80	0.9	1.4	3.00	3.75
C91	Lymphoid Leukaemia	173	%2.00	1.8	2.3	7.10	7.8	99	%0.90	1.1	1.3	4.05	4.60
C92-C94	Myeloid Leukaemia	228	%2.60	2.4	3.2	9.35	10.75	178	%1.70	1.9	2.5	7.35	8.40
C95	Leukaemia unspec.	116	%1.30	1.2	1.3	5.50	5.6	98	%0.90	1	1.1	4.60	4.80
Other	Other & unspecified	128	%1.50	1.4	2	4.60	5.55	153	%1.50	1.6	2.4	5.10	6.80

Cancer incidence among adults (>14 years), 2022.

Between January and December 2022, the total number of cancer incidence cases reported to the Saudi cancer registry among adults aged above 14 was 23352. Among those, 18552 cancer cases were Saudis and 4610 were non-Saudis, and unknown nationalities were reported in 190 cases. A total of 10650 (45.6%) cases were males and 12714 (54.4%) were females with a male to female ratio of 100 to 119.4, **Table 2.7.1**.

Table 2.7.1: Distribution of analyzed and non-analyzed adult cancer cases reported to Saudi cancer registry by nationality and gender, 2022.

Saudis						Unknown Nationality			Non-Saudis					
Analyzed			Non-Analyzed						Analyzed			Non-Analyzed		
Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
8280	10098	18378	90	84	174	89	101	190	2175	2426	4601	4	5	9

Table 2.7.2: Most common cancers among Saudi adults, 2022.

Sites	No.	%
Breast	3334	18.1
Colorectal	2532	13.8
Thyroid	1664	9.1
NHL	1040	5.7
Prostate	661	3.6
Corpus Uteri	647	3.5
Liver	641	3.5
Lung	623	3.4
Leukaemia	621	3.4
Kidney	583	3.2

Table 2.7.3: Top ten cancers reported among Saudi adults by gender, 2022.

Male	8280	%	Female	10098	%
Colorectal	1468	17.7	Breast	3280	32.5
Prostate	661	8.0	Thyroid	1278	12.7
NHL	591	7.1	Colorectal	1064	10.5
Bladder	473	5.7	Corpus Uteri	647	6.4
Lung	464	5.6	NHL	449	4.4
Liver	432	5.2	Ovary	298	3.0
Kidney	386	4.7	Leukaemia	255	2.5
Thyroid	386	4.7	Liver	209	2.1
Leukaemia	366	4.4	Brain, CNS	207	2.0
Hodgkin lymphoma	310	3.7	Kidney	197	2.0

Childhood cancers reported to the Saudi cancer registry (≤ 14 years), 2022.

A total of 1115 cancer cases were diagnosed among children aged between 0 and 14 accounting for 4.5% of the total number of cancers reported to the Saudi cancer registry in 2022. The reported incidence show that cancer was more common among boys than girls, 618 (55.4 %) cases were reported among boys and 497 (44.6%) were reported among girls. A total of 864 cancer cases were reported among Saudi children, 239 were among non-Saudis, and 12 cases were of unknown nationalities. The total number of analyzed cases was 1093 including 855 Saudis and 238 non-Saudis. Among Saudis, 468 (54.7 %) were boys and 387 (45.3 %) were girls, **Table 2.8.1**.

Table 2.8.1: Distribution of reported childhood cancer in Saudi Arabia by nationality and gender, 2022.

Saudis						Unknown Nationality			Non-Saudis					
Analyzed			Non-Analyzed						Analyzed			Non-Analyzed		
Boys	Girls	Total	Boys	Girls	Total	Boys	Girls	Total	Boys	Girls	Total	Boys	Girls	Total
468	387	855	4	5	9	5	7	12	141	97	238	0	1	1

Childhood cancers accounted for 4.4% of all cancer among Saudis. The leading cancer among Saudi children was leukemia (31.8 %), followed by brain tumors (18.2 %), then Hodgkin's lymphoma (8.1 %), and Bone (7.6%), **Table 2.8.2**.

Table 2.8.2: Top ten cancers among Saudi children, 2022.

Sites	No.	%
Leukaemia	271	31.8
Brain, CNS	155	18.2
Hodgkin lymphoma	69	8.1
Bone	65	7.6
NHL	58	6.8
Kidney	47	5.5
Connective,Soft tissue	37	4.3
Eye	24	2.8
Adrenal gland	24	2.8
Thyroid	13	1.5

Table 2.8.3: Distribution of top ten Childhood cancer sites by genders, 2022.

Male	468	%	Female	387	%
Leukaemia	151	32.3	Leukaemia	120	31.0
Brain, CNS	79	16.9	Brain, CNS	76	19.6
Hodgkin lymphoma	50	10.7	Bone	35	9.0
NHL	36	7.7	Kidney	28	7.2
Bone	30	6.4	NHL	22	5.7
Connective,Soft tissue	20	4.3	Hodgkin lymphoma	19	4.9
Kidney	19	4.1	Connective,Soft tissue	17	4.4
Eye	16	3.4	Adrenal gland	11	2.8
Adrenal gland	13	2.8	Eye	10	2.6
Testis	5	1.1	Thyroid	10	2.6

Table 2.8.4: Distribution of morphological types for the most common cancers reported among Saudi children by gender, 2022.

Primary Site	Code	Morphology	Male	%	Female	%
Leukaemia	98003	Leukemia, NOS	42	28	41	54
	98363	Precursor B-cell lymphoblastic leukemia	29	19	23	13
	98013	Acute leukemia, NOS	24	16	20	10
	98373	Precursor T-cell lymphoblastic leukemia	17	11	6	5
	98613	Acute myeloid leukemia, NOS	17	11	19	1
	98353	Precursor cell lymphoblastic leukemia, NOS	6	4	6	3
	98333	Prolymphocytic leukemia, B-cell type	4	3	-	1
	98263	Burkitt cell leukemia	3	2	-	13
	98663	Acute promyelocytic leukemia, t(17;15)(q22;q12-11)	3	2	1	100
	98633	Chronic myeloid leukemia, NOS	2	1.3	-	-
		Others	4	2.6	4	-
	Total	151	100.0	120	-	
Brain, CNS	93803	Glioma, malignant	18	22.8	25	32.9
	94703	Medulloblastoma, NOS	18	22.8	9	11.8
	94203	Fibrillary astrocytoma	8	10.1	10	13.2
	93913	Ependymoma, NOS	6	7.6	3	3.9
	80003	Neoplasm, malignant	4	5	5	7
	94003	Astrocytoma, NOS	4	5	6	8
	94403	Glioblastoma, NOS	4	5	5	7
	95003	Neuroblastoma, NOS	4	5	3	4
	90643	Germinoma	2	3	1	1
	94713	Desmoplastic nodular medulloblastoma	2	3	4	5
		Others	9	11	5	7
	Total	29	37	29	38	
Hodgkin lymphoma	96503	Hodgkin lymphoma, NOS	21	42	13	68
	96513	Hodgkin lymphoma, lymphocyte-rich	2	4	-	0
	96523	Hodgkin lymphoma, mixed cellularity, NOS	6	12	-	0
	96593	Hodgkin lymphoma, nodular lymphocyte predominance	10	20	2	11
	96633	Hodgkin lymphoma, nodular sclerosis, NOS	10	20	4	21
	96653	Hodgkin lymphoma, nodular sclerosis, grade 1	1	2	-	0
		Total	50	100	19	100
Thyroid	82603	Papillary adenocarcinoma, NOS	3	100	5	50
	80503	Papillary carcinoma, NOS	-	0	3	30
	80103	Carcinoma, NOS	-	0	1	10
	83403	Papillary carcinoma, follicular variant	-	0	1	10
		Total	3	100	10	100

Primary Site	Code	Morphology	Male	%	Female	%
Bone	91803	Osteosarcoma, NOS	10	33	13	37
	92603	Ewing sarcoma	10	33	12	34
	80003	Neoplasm, malignant	-	0	2	6
	88003	Sarcoma, NOS	2	7	1	3
	88033	Small cell sarcoma	1	3	1	3
	90853	Mixed germ cell tumor	-	0	1	3
	91813	Chondroblastic osteosarcoma	1	3	1	3
	91853	Small cell osteosarcoma	-	0	1	3
		Others	6	20	3	9
		Total	30	100	35	100
NHL	95903	Malignant lymphoma, NOS	12	33	5	23
	96803	Malignant lymphoma, large B-cell, diffuse, NOS	11	31	3	14
	97003	Mycosis fungoides	5	14	2	9
	96873	Burkitt lymphoma, NOS	3	8	1	5
	97023	Mature T-cell lymphoma, NOS	2	6	-	0
		Others	3	8	11	50
		Total	36	100	22	100
Kidney	89603	Nephroblastoma, NOS	14	74	26	93
	83123	Renal cell carcinoma, NOS	4	21	1	4
	89643	Clear cell sarcoma of kidney	-	0	1	4
	89633	Malignant rhabdoid tumor	1	5	-	0
		Total	19	100	28	100
Connective, Soft tissue	89003	Rhabdomyosarcoma, NOS	5	25	6	35
	95003	Neuroblastoma, NOS	4	20	1	6
	89103	Embryonal rhabdomyosarcoma, NOS	2	10.0	-	0.0
	89203	Alveolar rhabdomyosarcoma	2	10.0	-	0.0
	92523	Malignant tenosynovial giant cell tumor	2	10	-	0
	80003	Neoplasm, malignant	1	5	1	6
		Others	4	20	9	53
	Total	20	100	17	100	
Eye	95103	Retinoblastoma, NOS	7	44	4	40
	95113	Retinoblastoma, differentiated	4	25.0	3	30.0
	95123	Retinoblastoma, undifferentiated	4	25.0	3	30.0
	89003	Rhabdomyosarcoma, NOS	1	6.3	-	0.0
		Total	16	100.0	10	100.0
Adrenal gland	95003	Neuroblastoma, NOS	12	92.31	10	92.3
	80103	Carcinoma, NOS	1	7.692	1	7.69
		Total	13	100	11	100

International comparison of age-standardized incidence rates.

Figure 2.6.1: Comparison of ASR* for Saudi males with selected countries**





Figure 2.6.2: Comparison of ASR* for Saudi females with selected countries**





PART III

INCIDENCE OF MOST COMMON
CANCERS DIAGNOSED AMONG
SAUDI NATIONALS, 2022



Cancer incidence for most common sites among Saudi nationals, 2022.

This section demonstrates the most common cancers diagnosed among Saudi nationals during the period between January and December 2022. It shows the distribution of the most common cancers by gender and geographical area. Data presented as absolute numbers, relative frequency, and incidence rates. It also presents comparisons of cancer incidence among Saudis with cancer incidence reported from selected developed and developing countries.

Table 3.1: Most common cancer among Saudis by gender, 2022.

Sites	Male	Female	All	%
Breast	54	3280	3334	17.3
Colorectal	1470	1065	2535	13.2
Thyroid	389	1288	1677	8.7
Non-Hodgkin lymphoma	627	471	1098	5.7
Leukaemia	517	375	892	4.6
Prostate	661	-	661	3.4
Liver	437	213	650	3.4
Brain, Nervous system	367	283	650	3.4
Corpus Uteri	-	647	647	3.4
Kidney	405	225	630	3.3

Female breast cancer (C50).

Breast cancer was ranked first among Saudi females. There were 3280 female breast cancer cases. Breast cancer accounted for 17.3% of all cancers reported among Saudi nationals, and 31.3% of all cancers reported among females. The ASR was 49.7/100,000 for the Saudi female population.

The median age at diagnosis was 52 years (ranging between 18 and 106).

Figure 3.1.1: Age-Specific Incidence Rate (AIR) for breast cancer among Saudi females, 2022.





Table 3.1.1: Morphological distribution of breast cancer among Saudi females, 2022.

ICD-O-3	Morphology	NO.	%
85003	Infiltrating duct carcinoma, NOS	2708	82.6
85203	Lobular carcinoma, NOS	187	5.7
80103	Carcinoma, NOS	90	2.7
80003	Neoplasm, malignant	55	1.7
85213	Infiltrating ductular carcinoma	29	0.9
	Others	211	6.4
	Total	3280	100.0

Figure 3.1.2: Stage distribution of breast cancer among Saudi females, 2022.



Colorectal cancer (C18-C20).

Colorectal cancer was ranked first among Saudi males and third among Saudi females. There were 2535 cases of colorectal cancer accounting for 13.2% of all newly diagnosed cases in the year 2022 among Saudi nationals. It affected 1470 (58.0 %) males and 1065 (42.0 %) females with a male to female ratio of 138 to 100. The ASR was 26.2 /100,000 for males and 17.8 /100,000 for females.

The median age at diagnosis was 60 years in males (ranging between 13 and 104) and 59 years in females (ranging between 13 and 95).

Figure 3.2.1: Age-Specific Incidence Rate (AIR) for colorectal cancer among Saudi nationals, 2022.




Table 3.2.1: Morphological distribution of colorectal cancer among Saudi nationals, 2022.

ICD-O-3	Morphology	Male	%	Female	%
81403	Adenocarcinoma, NOS	1300	88.4	940	88.3
84803	Mucinous adenocarcinoma	45	3.1	47	4.4
80103	Carcinoma, NOS	27	1.8	10	0.9
82403	Carcinoid tumor, NOS	13	0.9	6	0.6
80003	Neoplasm, malignant	13	0.9	22	2.1
	Other	72	4.9	40	3.8
	Total	1470	100.0	1065	100.0

Figure 3.2.2: Stage distribution of colorectal cancer among Saudi nationals, 2022.





Figure 3.2.4 Comparison of ASR* For Colorectal Cancer Among Saudi Arabia With ASR In Selected Countries 2022



*ASR per 100,000

**Source for this information is summarized on page 56.

Thyroid cancer (C73).

Thyroid cancer was ranked second among Saudi females and ninth among Saudi males. There were 1677 thyroid cases of cancer accounting for 8.7% of all newly diagnosed cancers in 2022 among Saudi nationals. Thyroid cancer affected 1288 (76.8%) females and 389 (23.2%) males, with a female to male ratio of 331 to 100. The ASR was 16.5/100,000 for females and 5.4/100,000 for males. The median age at diagnosis was 43 years in females (ranging between 7 and 96) and 45 years in males (ranging between 6 and 84).

Figure 3.3.1: Age-Specific Incidence Rate (AIR) for thyroid cancer among Saudi nationals, 2022.




Table 3.3.1: Morphological distribution of thyroid cancer among Saudi nationals, 2022.

ICD-O-3	Morphology	Male	%	Female	%
82603	Papillary adenocarcinoma, NOS	167	42.9	526	40.8
80503	Papillary carcinoma, NOS	114	29.3	431	33.5
83403	Papillary carcinoma, follicular variant	28	7.2	90	7.0
83413	Papillary microcarcinoma	18	4.6	87	6.8
80103	Carcinoma, NOS	10	2.6	45	3.5
	Other	52	13.4	109	8.5
	Total	389	100.0	1288	100.0

Figure 3.3.2: Stage distribution of thyroid cancer among Saudi nationals, 2022.





Figure 3.3.4: Comparison of ASR* for thyroid cancer among Saudis with ASR in selected countries**



*ASR per 100,000

**Source for this information is summarized on page 56.

Non-Hodgkin Lymphoma (C82-C85; C96).

Non-Hodgkin Lymphoma (NHL) was ranked third among Saudi males and fifth among Saudi females. There were 1098 cases accounting for 5.7% of all cancers diagnosed among Saudi nationals in 2022. NHL affected 627 (57.1%) males, and 471 (42.9%) females, with a male to female ratio of 133 to 100. The ASR was 9.5 /100,000 for males and 7.1/100,000 for females.

The median age at diagnosis was 50 years in males (ranging between 1 and 96) and 56 years in females (ranging between 1 and 103).

Figure 3.4.1: Age-Specific Incidence Rate (AIR) for NHL among Saudi nationals, 2022.





Table 3.4.1: Morphological distribution of NHL among Saudi nationals, 2022.

Code	Morphology	Male	%	Female	%
96803	Malignant lymphoma, large B-cell, diffuse, NOS	312	49.8	228	48.4
95903	Malignant lymphoma, NOS	133	21.2	105	22.3
95913	Malignant lymphoma, non-Hodgkin, NOS	46	7.3	31	6.6
97003	Mycosis fungoides	44	7.0	30	6.4
97023	Mature T-cell lymphoma, NOS	19	3.0	6	1.3
	Others	73	11.6	71	15.1
	Total	627	100.0	471	100.0

Figure 3.4.4: Comparison of ASR* for NHL among Saudis with selected countries*



*ASR per 100,000
 **Source for this information is summarized on page 56.

Leukaemia (C91-C95).

Leukaemia was ranked fourth among Saudi males and the sixth among Saudi females. There were 892 cases accounting for 4.6% of all cancer cases diagnosed among Saudi nationals in 2022. Leukaemia affected 517 (58%) males and 375 (42%) females with a male to female ratio of 137 to 100. The ASR was 6.8 /100,000 for males and 4.9/100,000 for females.

The median age at diagnosis was 33.5 years in males (ranging between 0 and 100) and 37 years in females (ranging between 0 and 96).

Figure 3.5.1: Age-Specific Incidence Rate (AIR) for leukemia among Saudi nationals, 2022.





Table 3.5.1: Morphological distribution of leukaemia among Saudi nationals, 2022.

Code	Morphology	Male	%	Female	%
98613	Acute myeloid leukemia, NOS	107	20.7	77	20.5
98003	Leukemia, NOS	80	15.5	73	19.5
98633	Chronic myeloid leukemia, NOS	67	13.0	48	12.8
98233	B-cell chronic lymphocytic leukemia/small lymphocytic lymphom	50	9.7	32	8.5
98363	Precursor B-cell lymphoblastic leukemia	45	8.7	33	8.8
	Others	168	32.5	112	29.9
	Total	517	100.0	375	100

Figure 3.5.3: Comparison of ASR* for leukemia among Saudis with ASR in selected countries**



*ASR per 100,000

**Source for this information is summarized on page 56.

Prostate Cancer (C61).

Prostate Cancer was ranked second among Saudi males with 661 cases accounting for 7.6% of all cancer cases diagnosed among Saudi males and 3.4% of all cancer cases diagnosed among Saudi nationals in 2022.

The ASR was 13.4/100,000 for the Saudi male population.

The median age at diagnosis was 70 years (ranging between 21 and 101).

Figure 3.6.1: Age-Specific Incidence Rate (AIR) for Prostate cancer among Saudi males, 2022.




Table 3.6.1: Morphological distribution of Prostate cancer among Saudi males, 2022.

Code	Morphology	No	%
81403	Adenocarcinoma, NOS	563	85.2
85503	Acinar cell carcinoma	64	9.7
85513	Acinar cell cystadenocarcinoma	13	2.0
80003	Neoplasm, malignant	8	1.2
80103	Carcinoma, NOS	7	1.1
	others	6	0.9
	Total	661	100.0

Figure 3.6.2: Stage distribution of Prostate cancer among Saudi males, 2022.





Figure 3.6.4: Comparison of ASR* for Prostate cancer among Saudi males with ASR in selected countries**



*ASR per 100,000

**Source for this information is summarized on page 56.

Liver Cancer (C22)

Liver cancer was ranked seventh among Saudi males and ninth among Saudi females. There were 650 liver cancer cases accounting for 3.4% of all cancer cases diagnosed among Saudi nationals in 2022. Liver cancer affected 437 (67.2%) males and 213 (32.8%) females with a male to female ratio of 205 to 100. The ASR was 8.5/100,000 for males and 3.9/100,000 for females.

The median age at diagnosis was 67 years in males (ranging between 0 and 106) and 65 years in females (ranging between 0 and 98).

Figure 3.7.1: Age-Specific Incidence Rate (AIR) for liver cancer among Saudi nationals, 2022.




Table 3.7.1: Morphological distribution of liver cancer among Saudi nationals, 2022.

Code	Morphology	Male	%	Female	%
81703	Hepatocellular carcinoma, NOS	335	76.7	123	57.7
81403	Adenocarcinoma, NOS	47	10.8	47	22.1
81603	Cholangiocarcinoma	20	4.6	15	7.0
80103	Carcinoma, NOS	10	2.3	12	5.6
81803	Combined hepatocellular carcinoma and cholangiocarcinoma	6	1.4	5	2.3
	Others	19	4.3	11	5.2
	Total	437	100.0	213	100.0

Figure 3.7.2: Stage distribution of liver cancer among Saudi nationals, 2022.





Figure 3.7.4: Comparison of ASR* for liver cancer among Saudis with ASR in selected countries**



*ASR per 100,000

**Source for this information is summarized on page 56.

Brain, Central nervous system (C70-C72).

Brain, CNS cancer was ranked tenth among Saudi males and eighth among Saudi females. There were 650 cases accounting for 3.4% of all cancer cases diagnosed among Saudi nationals in 2022. Brain, CNS cancer affected 367 (56.5%) males and 283 (43.5%) females, with a ratio of male to female of 129.6 to 100. The ASR was 4.9/100,000 for males and 3.7/100,000 for females.

The median age at diagnosis was 40 years (ranging between 0 and 87) in males and 39 years (ranging between 0 and 114) in females.

Figure 3.8.1: Age-Specific Incidence Rate (AIR) for Brain, CNS among Saudi nationals, 2022.




Table 3.8.1: Morphological distribution of Brain, CNS among Saudi nationals, 2022.

Code	Morphology	Male	%	Female	%
94403	Glioblastoma, NOS	95	25.9	68	24.0
93803	Glioma, malignant	89	24.3	76	26.9
94203	Fibrillary astrocytoma	36	9.8	25	8.8
94003	Astrocytoma, NOS	31	8.4	22	7.8
94703	Medulloblastoma, NOS	18	4.9	9	3.2
	Others	98	26.7	83	29.3
	Total	367	100.0	283	100.0

Figure 3.8.2: Stage distribution of Brain, CNS among Saudi nationals, 2022.





Figure 3.8.4: Comparison of ASR* for Brain, CNS among Saudis with ASR in selected countries**



*ASR per 100,000

**Source for this information is summarized on page 56.

Corpus Uteri Cancer (C54).

Corpus Uteri Cancer was ranked fourth among Saudi females with 647 cases accounting for 6.2% of all cancer cases diagnosed among Saudi females and 3.4% of all cancer cases diagnosed among Saudi nationals in 2022. The ASR was 11.6/100,000 for the Saudi female population. The median age at diagnosis was 62 years (ranging between 32 and 94).

Figure 3.9.1: Age-Specific Incidence Rate (AIR) for Corpus Uteri Cancer among Saudi females, 2022.




Table 3.9.1: Morphological distribution of Corpus Uteri Cancer among Saudi females, 2022.

Code	Morphology	Female	%
83803	Endometrioid adenocarcinoma, NOS	428	66.2
81403	Adenocarcinoma, NOS	80	12.4
80103	Carcinoma, NOS	35	5.4
89803	Carcinosarcoma, NOS	31	4.8
83233	Mixed cell adenocarcinoma	10	1.5
	Others	63	9.7
	total	647	100.0

Figure 3.9.2: Stage distribution of Corpus Uteri Cancer among Saudi females, 2022.





Figure 3.9.4: Comparison of ASR* for Corpus Uteri Cancer among Saudi females with ASR in selected countries**



*ASR per 100,000

**Source for this information is summarized on page 56.

Kidney (C64).

Kidney cancer was ranked eighth among Saudi males and ninth among Saudi females. There were 630 cases accounting for 3.3% of all cancer cases diagnosed among Saudi nationals in 2022. Kidney cancer affected 405 (64.3%) males and 225 (35.7%) females, with a ratio of male to female of 180 to 100. The ASR was 6.7/100,000 for males and 3.3/100,000 for females.

The median age at diagnosis was 54 years (ranging between 0 and 97) in males and 53 years (ranging between 0 and 81) in females.

Table 3.10.1: Morphological distribution of Kidney Cancer among Saudi nationals, 2022.

Code	Morphology	Male	%	Female	%
83123	Renal cell carcinoma, NOS	309.0	76.3	156	69.3
83103	Clear cell adenocarcinoma, NOS	32.0	7.9	16	7.1
83173	Renal cell carcinoma, chromophobe type	22.0	5.4	13	5.8
89603	Nephroblastoma, NOS	14.0	3.5	26	11.6
82603	Papillary adenocarcinoma, NOS	10.0	2.5	5	2.2
	Others	18.0	4.4	9	4.0
	Total	405.0	100.0	225	100.0

Figure 3.10.2: Stage distribution of Kidney Cancer among Saudi nationals, 2022.





Figure 3.10.4: Comparison of ASR* for Kidney Cancer among Saudis with ASR in selected



*ASR per 100,000

**Source for this information is summarized on page 56.

PART IV

CANCER INCIDENCE AMONG NON-SAUDIS 2022



Cancer Incidence Among Non-Saudi Population, 2022.

Between January and December 2022, a total of 4849 cancer cases were reported among the Non-Saudi population, 10 cases were excluded from analysis due to In Situ and mismatch between ICD-O-3 and ICD-10 codes. Therefore, the total Number of Cases analyzed was 4839 Out of this 2316 (47.9 %) were males and 2523 (52.1 %) were females.

Taking into consideration the population structure of non-Saudis and the fact that cancer is primarily a disease of the elderly; the pattern of cancer had some significant differences. Those who were under 15 represented 15.2% of the population, those aged 60 and above represented 3.8%, and the 15 to 59 age group represented 81% of the non-Saudi population.

In 2022, approximately 4.9% of all cancers occurred before the age of 15 years, 22.6% occurred between the ages of 15 to 39 years, 54.4% were between the ages of 40 to 64 years, and 18.1% occurred after the age of 64 years. The median age at diagnosis was 52 years in males (ranging between 0 and 94) and 47 years in females (ranging between 0 and 95).

Table 4.1: Ten most common cancers among non-Saudi population, 2022.

Sites	No.	%
Breast	1026	21.2
Colorectal	543	11.2
leukaeamia	281	5.8
Thyroid	275	5.7
NHL	222	4.6
Brain, CNS	182	3.8
Lung	181	3.7
Prostate	173	3.6
Bladder	135	2.8
Kidney	133	2.7
Other Sites	1688	34.9


Table 4.2: Distribution of cancer cases among non-Saudi by nationality and gender, 2022.

Nationality	Male	%	Female	%	Total	%
Yemen	496	21.4	516	20.5	1012	20.9
Egypt	311	13.4	262	10.4	573	11.8
Syrian Arab Republic	275	11.9	271	10.7	546	11.3
Sudan	257	11.1	199	7.9	456	9.4
Philippines	92	4.0	290	11.5	382	7.9
Pakistan	123	5.3	109	4.3	232	4.8
India	82	3.5	96	3.8	178	3.7
Jordan	66	2.8	77	3.1	143	3.0
Bangladesh	112	4.8	27	1.1	139	2.9
Palestine	64	2.8	65	2.6	129	2.7
Myanmar	45	1.9	37	1.5	82	1.7
Indonesia	10	0.4	58	2.3	68	1.4
Lebanon	30	1.3	37	1.5	67	1.4
Ethiopia	10	0.4	46	1.8	56	1.2
Morocco	15	0.6	40	1.6	55	1.1
Eritrea	19	0.8	35	1.4	54	1.1
Other Nationalities	309	13.3	358	14.2	667	13.8
Total	2316	100.0	2523	100.0	4839	100.0

Table 4.3: Most common cancers among the non-Saudi population by gender, 2022.

Male	1962	%	Female	2253	%
colorectal	344	14.9	Breast	1013	40.2
leukaeamia	179	7.7	colorectal	199	7.9
Prostate	173	7.5	Thyroid	195	7.7
NHL	140	6.0	leukaeamia	102	4.0
Brain, CNS	120	5.2	NHL	82	3.3
Lung	118	5.1	Corpus Uteri	81	3.2
Bladder	112	4.8	Ovary	81	3.2
Kidney	99	4.3	Cervix Uteri	68	2.7
Other Skin	92	4.0	Lung	63	2.5
Liver	86	3.7	Brain, CNS	62	2.5
Other Sites	853	36.8	Other Sites	577	22.9

Figure 4.1: Age-Specific Incidence Rate (AIR) for all cancers among Non-Saudi population, 2022.





PART V
INCIDENCE TABLES



Table 5.1.1 Number Of Cases Among Saudi Males by Primary Site And Age Groups, 2022

ICD (10th)	Site	All Ages	Age unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total (%)
C00	Lip	13	0	0	0	0	0	0	0	1	2	0	0	1	1	0	5	0	3	%0.10
C01-C02	Tongue	78	0	0	0	1	0	0	2	6	1	9	6	7	8	10	8	11	9	%0.90
C03-C06	Mouth	66	0	0	0	0	1	1	3	1	1	3	2	5	6	6	13	8	16	%0.80
C07-C08	Salivary glands	28	0	0	0	1	0	1	0	2	2	3	3	1	3	3	6	0	3	%0.30
C09	Tonsil	7	0	0	0	0	0	0	1	0	1	0	0	0	0	2	2	1	0	%0.10
C10	Other Oropharynx	6	0	0	0	0	0	0	0	0	0	0	0	1	2	0	2	1	0	%0.10
C11	Nasopharynx	198	1	0	0	0	6	7	2	15	15	21	26	26	26	21	15	8	9	%2.30
C12-C13	Hypopharynx	12	0	0	0	0	0	0	0	0	0	1	0	2	2	1	1	1	4	%0.10
C14	Pharynx unspec.	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	%0.00
C15	Oesophagus	102	0	0	0	0	0	1	0	1	1	5	4	12	12	17	11	10	28	%1.20
C16	Stomach	230	0	0	0	0	0	1	3	8	12	10	16	20	29	33	22	22	54	%2.60
C17	Small intestine	68	0	0	0	0	0	0	2	2	5	6	4	13	6	6	7	6	11	%0.80
C18	Colon	895	1	0	0	2	2	8	12	22	36	60	78	78	109	115	135	92	145	%10.20
C19-C20	Rectum	575	1	0	0	0	0	3	7	15	30	45	60	56	91	80	68	51	68	%6.60
C21	Anus	22	0	0	0	0	0	0	1	3	0	2	0	0	4	4	4	2	2	%0.30
C22	Liver	437	0	2	3	0	0	2	6	3	4	7	16	28	48	57	70	72	119	%5.00
C23-C24	Gallbladder etc.	104	0	0	0	0	0	0	0	4	2	5	9	7	8	17	21	15	16	%1.20
C25	Pancreas	290	0	0	0	0	0	0	1	2	5	12	25	33	42	45	50	28	47	%3.30
C30-C31	Nose, sinuses etc.	21	0	0	0	0	0	1	2	2	1	1	0	3	0	3	2	1	5	%0.20
C32	Larynx	108	0	0	0	0	0	0	0	0	0	6	3	10	9	22	21	15	22	%1.20
C33-C34	Trachea,Bronchus,Lung	464	0	0	0	0	1	3	4	4	18	16	18	40	59	80	85	54	82	%5.30
C37-C38	Other Thoracic organs	38	0	4	1	0	1	2	1	6	5	2	2	0	5	0	2	2	5	%0.40
C40-C41	Bone	115	0	1	9	20	22	10	8	8	8	4	2	5	3	6	3	2	4	%1.30
C43	Melanoma of Skin	17	0	1	0	0	0	0	2	0	2	0	0	2	2	0	2	1	5	%0.20
C44	Other Skin	253	0	3	1	1	3	6	8	6	12	12	9	10	19	26	27	23	87	%2.90
C45	Mesothelioma	7	0	0	0	0	0	0	0	0	1	0	1	0	2	0	1	0	2	%0.10
C46	Kaposi sarcoma	36	0	0	0	0	0	1	2	1	1	1	4	3	5	1	3	3	11	%0.40
C47;C49	Connective,Soft tissue	137	0	9	6	5	10	5	8	6	13	6	14	15	6	12	9	5	8	%1.60
C50	Breast	54	2	0	0	0	0	0	2	1	4	3	5	5	5	8	6	3	10	%0.60
C60	Penis	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	%0.00
C61	Prostate	661	0	0	0	0	0	1	0	0	0	2	6	26	55	96	143	110	222	%7.60
C62	Testis	214	0	3	0	2	7	32	54	48	37	16	7	4	2	1	0	0	1	%2.40
C63	Other male genital	4	0	1	0	0	0	0	0	0	0	0	0	0	0	3	0	0	0	%0.00
C64	Kidney	405	0	14	3	2	0	4	5	22	21	31	42	59	56	42	41	28	35	%4.60
C65	Renal Pelvis	9	0	0	0	0	0	0	0	0	1	2	1	2	0	1	1	0	1	%0.10
C66	Ureter	7	0	0	0	0	0	0	0	0	0	0	0	1	1	0	3	0	2	%0.10
C67	Bladder	474	0	1	0	0	1	1	1	11	7	14	33	34	57	68	71	61	114	%5.40
C68	Other Urinary organs	5	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	1	1	%0.10
C69	Eye	28	0	15	0	1	0	0	0	1	1	1	1	0	0	1	1	2	4	%0.30
C70-C72	Brain, Nervous system	367	0	30	32	17	10	17	23	25	26	29	21	29	28	34	17	9	20	%4.20
C73	Thyroid	389	0	0	1	2	1	13	28	54	41	52	51	35	38	27	20	12	14	%4.40
C74	Adrenal gland	24	0	10	2	1	1	2	1	0	0	1	2	1	0	0	1	0	2	%0.30
C75	Other Endocrine	17	0	1	1	1	2	0	0	3	2	1	2	1	1	0	0	2	0	%0.20
C81	Hodgkin disease	360	0	2	14	34	38	45	34	45	36	30	17	22	17	7	4	4	11	%4.10
C82-C85;C96	Non-Hodgkin lymphoma	627	1	5	12	19	23	32	36	48	40	41	45	48	50	62	53	45	67	%7.20
C88	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%0.00
C90	Multiple Myeloma	127	0	0	0	0	0	0	1	7	3	8	9	15	17	16	19	11	21	%1.50
C91	Lymphoid Leukaemia	173	0	32	14	13	11	5	5	4	7	10	8	10	12	11	8	6	17	%2.00
C92-C94	Myeloid Leukaemia	228	1	13	6	7	16	15	16	19	7	19	19	18	17	15	19	9	12	%2.60
C95	Leukaemia unspec.	116	0	44	12	10	10	8	6	3	3	4	1	2	4	3	0	2	4	%1.30
Other	Other & unspecified	128	0	18	0	3	3	4	1	7	2	7	12	10	12	13	11	8	17	%1.50
		----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----
All	All sites Total	8748	7	209	117	142	169	231	288	416	416	508	584	701	881	976	1014	748	1341	%100.00
Not C44	All sites but C44	8495	7	206	116	141	166	225	280	410	404	496	575	691	862	950	987	725	1254	%97.10

Table 5.1.2 Number Of Cases Among Saudi Females by Primary Site And Age Groups, 2022

ICD (10th)	Site	All Ages	Age unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total (%)	
C00	Lip	12	0	0	0	0	0	0	0	1	0	0	1	1	0	1	2	1	5	%0.10	
C01-C02	Tongue	65	1	0	0	0	0	1	1	3	4	5	4	10	9	12	4	2	9	%0.60	
C03-C06	Mouth	59	1	0	1	0	1	0	3	1	2	6	7	7	4	4	7	6	9	%0.60	
C07-C08	Salivary glands	20	0	0	0	2	2	0	0	1	3	4	3	3	1	0	0	0	1	%0.20	
C09	Tonsil	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	%0.00	
C10	Other Oropharynx	3	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	2	%0.00	
C11	Nasopharynx	51	0	0	0	1	3	2	0	3	2	4	7	10	5	7	4	2	1	%0.50	
C12-C13	Hypopharynx	8	0	0	0	0	0	0	0	2	1	3	1	0	0	0	1	0	0	%0.10	
C14	Pharynx unspec.	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	%0.00	
C15	Oesophagus	50	0	0	0	0	0	0	1	3	2	4	3	2	6	9	4	5	11	%0.50	
C16	Stomach	137	0	0	0	0	0	3	4	6	10	12	10	15	13	15	17	11	21	%1.30	
C17	Small intestine	52	0	0	0	0	0	0	2	3	3	8	6	3	5	7	0	4	11	%0.50	
C18	Colon	741	1	0	0	1	1	1	12	22	29	52	57	90	113	107	90	66	99	%7.10	
C19-C20	Rectum	324	3	0	0	0	0	0	5	4	12	27	28	49	39	55	31	26	45	%3.10	
C21	Anus	11	0	0	0	0	0	0	0	1	0	0	1	0	1	4	2	0	2	%0.10	
C22	Liver	213	1	4	0	0	0	0	2	3	3	11	9	9	21	36	41	27	46	%2.00	
C23-C24	Gallbladder etc.	110	0	0	0	0	0	0	0	1	0	4	6	7	15	20	18	14	25	%1.00	
C25	Pancreas	189	0	0	0	0	0	2	0	3	4	17	8	18	31	24	31	18	33	%1.80	
C30-C31	Nose, sinuses etc.	6	0	0	0	1	0	0	0	0	0	0	0	1	0	1	1	1	1	%0.10	
C32	Larynx	8	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0	1	3	%0.10	
C33-C34	Trachea,Bronchus,Lung	159	0	0	0	0	0	2	4	3	7	10	12	19	16	25	16	18	27	%1.50	
C37-C38	Other Thoracic organs	26	0	2	1	2	0	1	0	3	2	2	3	4	1	2	3	0	0	%0.20	
C40-C41	Bone	108	1	6	10	19	12	7	5	11	7	4	9	1	5	2	4	2	3	%1.00	
C43	Melanoma of Skin	16	0	0	0	0	0	0	0	1	1	0	0	0	6	1	1	4	2	%0.20	
C44	Other Skin	151	1	0	1	1	1	1	1	3	7	10	6	10	13	14	20	17	45	%1.40	
C45	Mesothelioma	3	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	1	%0.00	
C46	Kaposi sarcoma	6	0	1	0	0	1	0	0	0	0	0	0	0	0	0	1	0	3	%0.10	
C47;C49	Connective,Soft tissue	113	0	12	1	4	5	6	6	5	9	11	3	9	13	8	5	3	13	%1.10	
C50	Breast	3280	8	0	0	0	2	17	35	139	278	399	487	456	438	404	266	136	215	%31.30	
C51	Vulva	14	0	0	0	0	0	0	0	1	1	2	1	1	2	3	2	0	1	%0.10	
C52	Vagina	13	0	1	0	0	0	0	0	0	3	0	2	1	2	0	1	1	2	%0.10	
C53	Cervix Uteri	157	2	0	0	0	0	1	5	6	12	16	15	25	23	11	21	8	12	%1.50	
C54	Corpus Uteri	647	2	0	0	0	0	0	0	6	23	27	40	58	115	134	112	64	66	%6.20	
C55	Uterus unspec.	160	0	0	0	0	2	1	1	2	4	8	9	15	25	33	28	18	14	%1.50	
C56	Ovary	300	1	1	1	0	14	13	15	13	30	23	38	32	36	28	20	18	17	%2.90	
C57	Other Female Genital	31	0	0	0	0	0	2	0	0	1	2	5	2	3	6	5	1	4	%0.30	
C58	Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%0.00	
C64	Kidney	225	0	14	11	3	4	0	7	10	12	24	12	27	25	20	21	15	20	%2.10	
C65	Renal Pelvis	6	0	0	0	0	1	0	0	0	0	1	0	1	0	0	1	1	1	%0.10	
C66	Ureter	6	0	0	0	0	0	0	0	0	0	0	0	0	1	2	1	1	1	%0.10	
C67	Bladder	88	0	0	0	1	0	2	2	1	4	7	3	3	13	9	9	7	27	%0.80	
C68	Other Urinary organs	2	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	%0.00	
C69	Eye	18	0	10	0	0	0	1	0	0	0	1	0	2	2	0	0	0	2	%0.20	
C70-C72	Brain, Nervous system	283	0	29	28	19	13	8	8	17	23	21	20	22	16	18	15	12	14	%2.70	
C73	Thyroid	1288	0	0	1	9	29	65	120	131	158	167	161	140	112	84	44	33	34	%12.30	
C74	Adrenal gland	27	0	6	3	2	0	1	1	1	3	1	3	2	2	0	1	0	1	%0.30	
C75	Other Endocrine	9	0	0	1	0	0	0	0	1	1	3	0	0	1	0	0	0	2	%0.10	
C81	Hodgkin disease	200	0	1	5	13	24	37	29	13	14	13	10	7	4	7	9	3	11	%1.90	
C82-C85;C96	Non-Hodgkin lymphoma	471	0	9	3	10	14	19	22	24	27	27	29	42	53	45	51	28	68	%4.50	
C88	Immunoproliferative dis.	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	%0.00	
C90	Multiple Myeloma	85	0	0	0	0	0	0	1	0	2	3	10	14	14	16	9	6	10	%0.80	
C91	Lymphoid Leukaemia	99	0	18	12	5	6	2	1	4	1	5	2	8	11	6	5	6	7	%0.90	
C92-C94	Myeloid Leukaemia	178	0	6	10	8	8	3	5	11	13	19	8	21	21	14	11	10	10	%1.70	
C95	Leukaemia unspec.	98	0	35	21	5	6	5	2	2	5	2	3	3	2	1	4	0	2	%0.90	
Other	Other & unspecified	153	1	9	2	4	1	5	3	6	9	10	5	15	17	16	18	16	16	%1.50	
		----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----
All	All sites Total	10485	23	164	112	111	150	208	303	472	732	975	1047	1165	1260	1215	958	613	977	%100.00	
Not C44	All sites but C44	10334	22	164	111	110	149	207	302	469	725	965	1041	1155	1247	1201	938	596	932	%98.60	

Table 5.1.3 Age-Specific Incidence Rate (AIR), Age Standardised Incidence Rate (ASR) Among Saudi Males (per 100,000) by Primary Site and Age groups, 2022

ICD (10th)	Site	All Ages	Age unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World	
C00	Lip	13	0	0	0	0	0	0	0	0.1	0.3	0	0	0.3	0.4	0	3.9	0	2.5	0.1	0.2	
C01-C02	Tongue	78	0	0	0	0.1	0	0	0.2	0.8	0.1	1.7	1.6	2.3	3.2	5.4	6.3	14.6	7.4	0.8	1.4	
C03-C06	Mouth	66	0	0	0	0	0.1	0.1	0.3	0.1	0.1	0.6	0.5	1.6	2.4	3.2	10.2	10.6	13.2	0.7	1.2	
C07-C08	Salivary glands	28	0	0	0	0.1	0	0.1	0	0.3	0.3	0.6	0.8	0.3	1.2	1.6	4.7	0	2.5	0.3	0.5	
C09	Tonsil	7	0	0	0	0	0	0	0.1	0	0.1	0	0	0	0	1.1	1.6	1.3	0	0.1	0.1	
C10	Other Oropharynx	6	0	0	0	0	0	0	0	0	0	0	0	0.3	0.8	0	1.6	1.3	0	0.1	0.1	
C11	Nasopharynx	198	1	0	0	0	0.6	0.8	0.2	1.9	2.2	3.9	6.8	8.4	10.3	11.2	11.8	10.6	7.4	2.1	3	
C12-C13	Hypopharynx	12	0	0	0	0	0	0	0	0	0	0.2	0	0.6	0.8	0.5	0.8	1.3	3.3	0.1	0.2	
C14	Pharynx unspec.	2	0	0	0	0	0	0	0	0	0	0	0	0	0.4	0	0.8	0	0	0	0	
C15	Oesophagus	102	0	0	0	0	0	0.1	0	0.1	0.1	0.9	1	3.9	4.8	9.1	8.7	13.3	23	1.1	1.9	
C16	Stomach	230	0	0	0	0	0	0.1	0.3	1	1.8	1.9	4.2	6.4	11.5	17.7	17.3	29.2	44.4	2.4	4.1	
C17	Small intestine	68	0	0	0	0	0	0	0.2	0.3	0.7	1.1	1	4.2	2.4	3.2	5.5	8	9.1	0.7	1.1	
C18	Colon	895	1	0	0	0.2	0.2	0.9	1.4	2.9	5.3	11.2	20.5	25.1	43.3	61.6	106.2	122	119.3	9.5	16.1	
C19-C20	Rectum	575	1	0	0	0	0	0.3	0.8	1.9	4.4	8.4	15.7	18	36.1	42.8	53.5	67.6	56	6.1	10.1	
C21	Anus	22	0	0	0	0	0	0	0.1	0.4	0	0.4	0	0	1.6	2.1	3.1	2.7	1.6	0.2	0.4	
C22	Liver	437	0	0.2	0.3	0	0	0.2	0.7	0.4	0.6	1.3	4.2	9	19.1	30.5	55.1	95.5	97.9	4.6	8.5	
C23-C24	Gallbladder etc.	104	0	0	0	0	0	0	0	0.5	0.3	0.9	2.4	2.3	3.2	9.1	16.5	19.9	13.2	1.1	2	
C25	Pancreas	290	0	0	0	0	0	0	0.1	0.3	0.7	2.2	6.6	10.6	16.7	24.1	39.3	37.1	38.7	3.1	5.5	
C30-C31	Nose, sinuses etc.	21	0	0	0	0	0	0.1	0.2	0.3	0.1	0.2	0	1	0	1.6	1.6	1.3	4.1	0.2	0.3	
C32	Larynx	108	0	0	0	0	0	0	0	0	0	1.1	0.8	3.2	3.6	11.8	16.5	19.9	18.1	1.1	2.1	
C33-C34	Trachea,Bronchus,Lung	464	0	0	0	0	0.1	0.3	0.5	0.5	2.7	3	4.7	12.9	23.4	42.8	66.9	71.6	67.5	4.9	8.8	
C37-C38	Other Thoracic organs	38	0	0.4	0.1	0	0.1	0.2	0.1	0.8	0.7	0.4	0.5	0	2	0	1.6	2.7	4.1	0.4	0.5	
C40-C41	Bone	115	0	0.1	0.8	1.9	2.3	1.2	0.9	1	1.2	0.7	0.5	1.6	1.2	3.2	2.4	2.7	3.3	1.2	1.3	
C43	Melanoma of Skin	17	0	0.1	0	0	0	0	0.2	0	0.3	0	0	0.6	0.8	0	1.6	1.3	4.1	0.2	0.3	
C44	Other Skin	253	0	0.3	0.1	0.1	0.3	0.7	0.9	0.8	1.8	2.2	2.4	3.2	7.5	13.9	21.2	30.5	71.6	2.7	4.3	
C45	Mesothelioma	7	0	0	0	0	0	0	0	0	0.1	0	0.3	0	0.8	0	0.8	0	1.6	0.1	0.1	
C46	Kaposi sarcoma	36	0	0	0	0	0	0.1	0.2	0.1	0.1	0.2	1	1	2	0.5	2.4	4	9.1	0.4	0.6	
C47;C49	Connective,Soft tissue	137	0	0.8	0.5	0.5	1.1	0.6	0.9	0.8	1.9	1.1	3.7	4.8	2.4	6.4	7.1	6.6	6.6	1.5	1.9	
C50	Breast	54	2	0	0	0	0	0	0.2	0.1	0.6	0.6	1.3	1.6	2	4.3	4.7	4	8.2	0.6	0.9	
C60	Penis	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.3	0.8	0	0	
C61	Prostate	661	0	0	0	0	0	0.1	0	0	0	0.4	1.6	8.4	21.8	51.4	112.5	145.9	182.7	7	13.4	
C62	Testis	214	0	0.3	0	0.2	0.7	3.7	6.3	6.2	5.5	3	1.8	1.3	0.8	0.5	0	0	0.8	2.3	2	
C63	Other male genital	4	0	0.1	0	0	0	0	0	0	0	0	0	0	0	1.6	0	0	0	0	0.1	
C64	Kidney	405	0	1.3	0.3	0.2	0	0.5	0.6	2.9	3.1	5.8	11	19	22.2	22.5	32.3	37.1	28.8	4.3	6.7	
C65	Renal Pelvis	9	0	0	0	0	0	0	0	0	0.1	0.4	0.3	0.6	0	0.5	0.8	0	0.8	0.1	0.1	
C66	Ureter	7	0	0	0	0	0	0	0	0	0	0	0	0.3	0.4	0	2.4	0	1.6	0.1	0.1	
C67	Bladder	474	0	0.1	0	0	0.1	0.1	0.1	1.4	1	2.6	8.7	11	22.6	36.4	55.9	80.9	93.8	5	8.9	
C68	Other Urinary organs	5	0	0	0	0	0	0	0	0	0	0	0	0.3	0.4	0.5	0	1.3	0.8	0.1	0.1	
C69	Eye	28	0	1.4	0	0.1	0	0	0	0.1	0.1	0.2	0.3	0	0	0.5	0.8	2.7	3.3	0.3	0.4	
C70-C72	Brain, Nervous system	367	0	2.7	2.8	1.6	1.1	2	2.7	3.2	3.8	5.4	5.5	9.3	11.1	18.2	13.4	11.9	16.5	3.9	4.9	
C73	Thyroid	389	0	0	0.1	0.2	0.1	1.5	3.3	7	6	9.7	13.4	11.3	15.1	14.5	15.7	15.9	11.5	4.1	5.4	
C74	Adrenal gland	24	0	0.9	0.2	0.1	0.1	0.2	0.1	0	0	0.2	0.5	0.3	0	0	0.8	0	1.6	0.3	0.3	
C75	Other Endocrine	17	0	0.1	0.1	0.1	0.2	0	0	0.4	0.3	0.2	0.5	0.3	0.4	0	0	2.7	0	0.2	0.2	
C81	Hodgkin disease	360	0	0.2	1.2	3.2	4	5.2	4	5.8	5.3	5.6	4.5	7.1	6.7	3.7	3.1	5.3	9.1	3.8	4	
C82-C85;C96	Non-Hodgkin lymphoma	627	1	0.5	1	1.8	2.4	3.7	4.2	6.2	5.9	7.7	11.8	15.5	19.8	33.2	41.7	59.7	55.1	6.7	9.5	
C88	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C90	Multiple Myeloma	127	0	0	0	0	0	0	0.1	0.9	0.4	1.5	2.4	4.8	6.7	8.6	14.9	14.6	17.3	1.3	2.3	
C91	Lymphoid Leukaemia	173	0	2.9	1.2	1.2	1.2	0.6	0.6	0.5	1	1.9	2.1	3.2	4.8	5.9	6.3	8	14	1.8	2.3	
C92-C94	Myeloid Leukaemia	228	1	1.2	0.5	0.7	1.7	1.7	1.9	2.5	1	3.6	5	5.8	6.7	8	14.9	11.9	9.9	2.4	3.2	
C95	Leukaemia unspec.	116	0	4	1	0.9	1.1	0.9	0.7	0.4	0.4	0.7	0.3	0.6	1.6	1.6	0	2.7	3.3	1.2	1.3	
Other	Other & unspecified	128	0	1.6	0	0.3	0.3	0.5	0.1	0.9	0.3	1.3	3.1	3.2	4.8	7	8.7	10.6	14	1.4	2	
		----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----
All	All sites Total	8748	7	19	10	13	18	27	34	54	61	95	153	226	350	523	798	992	1103	92.8	144.9	
Not C44	All sites but C44	8495	7	19	10	13	18	26	33	53	60	93	151	223	342	509	776	961	1032	90.1	140.5	

Table 5.1.4 Age-Specific Incidence Rate (AIR), Age Standardised Incidence Rate (ASR) Among Saudi Females (per 100,000) by Primary Site and Age groups, 2022

ICD (10th)	Site	All Ages	Age unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World	
C00	Lip	12	0	0	0	0	0	0	0	0.1	0	0	0.2	0.3	0	0.5	1.5	1.2	4	0.1	0.2	
C01-C02	Tongue	65	1	0	0	0	0	0.1	0.1	0.4	0.6	0.9	1	2.9	3.3	5.9	3.1	2.5	7.2	0.7	1	
C03-C06	Mouth	59	1	0	0.1	0	0.1	0	0.4	0.1	0.3	1.1	1.7	2	1.4	2	5.4	7.5	7.2	0.6	1	
C07-C08	Salivary glands	20	0	0	0	0.2	0.2	0	0	0.1	0.4	0.7	0.7	0.9	0.4	0	0	0	0.8	0.2	0.2	
C09	Tonsil	2	0	0	0	0	0	0	0	0	0	0	0	0	0.4	0	0	1.2	0	0	0	
C10	Other Oropharynx	3	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	1.6	0	0	
C11	Nasopharynx	51	0	0	0	0.1	0.3	0.2	0	0.4	0.3	0.7	1.7	2.9	1.8	3.4	3.1	2.5	0.8	0.5	0.8	
C12-C13	Hypopharynx	8	0	0	0	0	0	0	0	0.3	0.1	0.6	0.2	0	0	0	0.8	0	0	0.1	0.1	
C14	Pharynx unspec.	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.8	0	1.6	0	0.1	
C15	Oesophagus	50	0	0	0	0	0	0	0.1	0.4	0.3	0.7	0.7	0.6	2.2	4.4	3.1	6.2	8.8	0.5	0.8	
C16	Stomach	137	0	0	0	0	0	0.4	0.5	0.8	1.5	2.2	2.5	4.4	4.7	7.4	13.1	13.7	16.7	1.5	2.2	
C17	Small intestine	52	0	0	0	0	0	0	0.2	0.4	0.4	1.5	1.5	0.9	1.8	3.4	0	5	8.8	0.6	0.8	
C18	Colon	741	1	0	0	0.1	0.1	0.1	1.4	2.9	4.3	9.6	14.1	26.2	40.8	52.5	69.3	82.4	78.9	7.9	12.4	
C19-C20	Rectum	324	3	0	0	0	0	0	0.6	0.5	1.8	5	6.9	14.3	14.1	27	23.9	32.5	35.9	3.5	5.4	
C21	Anus	11	0	0	0	0	0	0	0	0.1	0	0	0.2	0	0.4	2	1.5	0	1.6	0.1	0.2	
C22	Liver	213	1	0.4	0	0	0	0	0.2	0.4	0.4	2	2.2	2.6	7.6	17.7	31.6	33.7	36.7	2.3	3.9	
C23-C24	Gallbladder etc.	110	0	0	0	0	0	0	0	0.1	0	0.7	1.5	2	5.4	9.8	13.9	17.5	19.9	1.2	2	
C25	Pancreas	189	0	0	0	0	0	0.2	0	0.4	0.6	3.1	2	5.2	11.2	11.8	23.9	22.5	26.3	2	3.3	
C30-C31	Nose, sinuses etc.	6	0	0	0	0.1	0	0	0	0	0	0	0	0.3	0	0.5	0.8	1.2	0.8	0.1	0.1	
C32	Larynx	8	0	0	0	0	0	0	0	0	0	0	0	0	1.1	0.5	0	1.2	2.4	0.1	0.1	
C33-C34	Trachea,Bronchus,Lung	159	0	0	0	0	0	0.2	0.5	0.4	1	1.8	3	5.5	5.8	12.3	12.3	22.5	21.5	1.7	2.7	
C37-C38	Other Thoracic organs	26	0	0.2	0.1	0.2	0	0.1	0	0.4	0.3	0.4	0.7	1.2	0.4	1	2.3	0	0	0.3	0.3	
C40-C41	Bone	108	1	0.6	0.9	1.8	1.3	0.8	0.6	1.5	1	0.7	2.2	0.3	1.8	1	3.1	2.5	2.4	1.2	1.2	
C43	Melanoma of Skin	16	0	0	0	0	0	0	0	0.1	0.1	0	0	0	2.2	0.5	0.8	5	1.6	0.2	0.3	
C44	Other Skin	151	1	0	0.1	0.1	0.1	0.1	0.1	0.4	1	1.8	1.5	2.9	4.7	6.9	15.4	21.2	35.9	1.6	2.6	
C45	Mesothelioma	3	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0.5	0	0	0.8	0	0	
C46	Kaposi sarcoma	6	0	0.1	0	0	0.1	0	0	0	0	0	0	0	0	0	0.8	0	2.4	0.1	0.1	
C47;C49	Connective,Soft tissue	113	0	1.1	0.1	0.4	0.5	0.7	0.7	0.7	1.3	2	0.7	2.6	4.7	3.9	3.9	3.7	10.4	1.2	1.5	
C50	Breast	3280	8	0	0	0	0.2	2	4.2	18.3	41.2	73.5	120.5	132.9	158.3	198.4	204.9	169.9	171.4	35.1	49.7	
C51	Vulva	14	0	0	0	0	0	0	0	0.1	0.1	0.4	0.2	0.3	0.7	1.5	1.5	0	0.8	0.1	0.2	
C52	Vagina	13	0	0.1	0	0	0	0	0	0	0.4	0	0.5	0.3	0.7	0	0.8	1.2	1.6	0.1	0.2	
C53	Cervix Uteri	157	2	0	0	0	0	0.1	0.6	0.8	1.8	2.9	3.7	7.3	8.3	5.4	16.2	10	9.6	1.7	2.4	
C54	Corpus Uteri	647	2	0	0	0	0	0	0	0.8	3.4	5	9.9	16.9	41.6	65.8	86.3	79.9	52.6	6.9	11.6	
C55	Uterus unspec.	160	0	0	0	0	0.2	0.1	0.1	0.3	0.6	1.5	2.2	4.4	9	16.2	21.6	22.5	11.2	1.7	2.9	
C56	Ovary	300	1	0.1	0.1	0	1.5	1.5	1.8	1.7	4.4	4.2	9.4	9.3	13	13.7	15.4	22.5	13.5	3.2	4.3	
C57	Other Female Genital	31	0	0	0	0	0	0.2	0	0	0.1	0.4	1.2	0.6	1.1	2.9	3.9	1.2	3.2	0.3	0.5	
C58	Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C64	Kidney	225	0	1.3	1	0.3	0.4	0	0.8	1.3	1.8	4.4	3	7.9	9	9.8	16.2	18.7	15.9	2.4	3.3	
C65	Renal Pelvis	6	0	0	0	0	0.1	0	0	0	0	0.2	0	0.3	0	0	0.8	1.2	0.8	0.1	0.1	
C66	Ureter	6	0	0	0	0	0	0	0	0	0	0	0	0	0.4	1	0.8	1.2	0.8	0.1	0.1	
C67	Bladder	88	0	0	0	0.1	0	0.2	0.2	0.1	0.6	1.3	0.7	0.9	4.7	4.4	6.9	8.7	21.5	0.9	1.4	
C68	Other Urinary organs	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	
C69	Eye	18	0	0.9	0	0	0	0.1	0	0	0	0.2	0	0.6	0.7	0	0	0	1.6	0.2	0.2	
C70-C72	Brain, Nervous system	283	0	2.7	2.5	1.8	1.4	0.9	0.9	2.2	3.4	3.9	4.9	6.4	5.8	8.8	11.6	15	11.2	3	3.7	
C73	Thyroid	1288	0	0	0.1	0.9	3.2	7.6	14.2	17.3	23.4	30.8	39.8	40.8	40.5	41.2	33.9	41.2	27.1	13.8	16.5	
C74	Adrenal gland	27	0	0.6	0.3	0.2	0	0.1	0.1	0.1	0.4	0.2	0.7	0.6	0.7	0	0.8	0	0.8	0.3	0.3	
C75	Other Endocrine	9	0	0	0.1	0	0	0	0	0.1	0.1	0.6	0	0	0.4	0	0	0	1.6	0.1	0.1	
C81	Hodgkin disease	200	0	0.1	0.5	1.3	2.6	4.4	3.4	1.7	2.1	2.4	2.5	2	1.4	3.4	6.9	3.7	8.8	2.1	2.3	
C82-C85;C96	Non-Hodgkin lymphoma	471	0	0.8	0.3	1	1.5	2.2	2.6	3.2	4	5	7.2	12.2	19.2	22.1	39.3	35	54.2	5	7.1	
C88	Immunoproliferative dis.	1	0	0	0	0	0	0	0	0	0	0	0	0	0.4	0	0	0	0	0	0	
C90	Multiple Myeloma	85	0	0	0	0	0	0	0.1	0	0.3	0.6	2.5	4.1	5.1	7.9	6.9	7.5	8	0.9	1.4	
C91	Lymphoid Leukaemia	99	0	1.7	1.1	0.5	0.7	0.2	0.1	0.5	0.1	0.9	0.5	2.3	4	2.9	3.9	7.5	5.6	1.1	1.3	
C92-C94	Myeloid Leukaemia	178	0	0.6	0.9	0.8	0.9	0.4	0.6	1.5	1.9	3.5	2	6.1	7.6	6.9	8.5	12.5	8	1.9	2.5	
C95	Leukaemia unspec.	98	0	3.3	1.9	0.5	0.7	0.6	0.2	0.3	0.7	0.4	0.7	0.9	0.7	0.5	3.1	0	1.6	1	1.1	
Other	Other & unspecified	153	1	0.8	0.2	0.4	0.1	0.6	0.4	0.8	1.3	1.8	1.2	4.4	6.1	7.9	13.9	20	12.8	1.6	2.4	
		----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----
All	All sites Total	10485	23	15	10	11	16	24	36	62	109	180	259	340	455	597	738	766	779	112.1	159.1	
Not C44	All sites but C44	10334	22	15	10	11	16	24	36	62	107	178	258	337	451	590	722	744	743	110.5	156.6	

Table 5.4.1 Number Of Cases Among Non-Saudi Males by Primary Site And Age Groups, 2022

ICD (10th)	Site	All Ages	Age unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total (%)	
C00	Lip	14	0	0	0	0	0	0	0	0	3	1	0	5	2	1	2	0	0	%0.60	
C01-C02	Tongue	34	0	0	0	0	0	0	0	1	5	3	5	3	4	3	5	3	2	%1.50	
C03-C06	Mouth	17	0	1	0	0	0	1	1	2	2	0	4	0	1	3	1	2	0	%0.70	
C07-C08	Salivary glands	17	0	0	0	0	0	0	0	2	2	1	3	1	3	2	1	1	1	%0.70	
C09	Tonsil	2	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	%0.10	
C10	Other Oropharynx	3	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	0	0	%0.10	
C11	Nasopharynx	56	0	0	0	1	0	1	2	3	1	11	7	11	8	7	2	0	2	%2.40	
C12-C13	Hypopharynx	2	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	%0.10	
C14	Pharynx unspec.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%0.00	
C15	Oesophagus	20	0	0	0	0	0	0	1	2	0	1	1	5	2	4	2	2	0	%0.90	
C16	Stomach	74	0	0	0	0	0	0	2	7	7	3	10	13	10	13	4	4	1	%3.20	
C17	Small intestine	21	0	0	0	0	0	0	0	0	0	2	2	1	6	3	1	2	4	%0.90	
C18	Colon	231	0	0	0	0	0	1	8	9	15	24	22	26	28	44	24	17	12	%10.00	
C19-C20	Rectum	113	0	0	0	0	0	0	3	5	8	8	12	20	22	11	9	10	5	%4.90	
C21	Anus	12	0	0	0	0	0	0	0	0	1	1	1	1	3	2	1	2	0	%0.50	
C22	Liver	86	0	1	0	0	0	0	2	2	4	6	6	11	11	16	8	13	7	%3.70	
C23-C24	Gallbladder etc.	17	0	0	0	0	0	0	0	0	0	0	4	3	3	3	0	4	0	%0.70	
C25	Pancreas	55	0	0	0	0	0	0	1	1	4	0	6	4	7	9	11	6	5	%2.40	
C30-C31	Nose, sinuses etc.	6	0	0	0	0	0	0	0	4	0	1	1	0	0	0	0	0	0	%0.30	
C32	Larynx	22	0	0	0	0	0	0	0	0	2	1	4	3	5	1	2	2	2	%0.90	
C33-C34	Trachea,Bronchus,Lung	118	0	0	1	0	0	1	4	3	3	8	7	21	16	15	14	16	9	%5.10	
C37-C38	Other Thoracic organs	21	2	0	0	0	1	1	2	2	4	3	1	2	0	1	1	0	0	%0.90	
C40-C41	Bone	52	1	1	1	8	5	3	4	3	4	7	6	2	1	3	3	0	0	%2.20	
C43	Melanoma of Skin	12	0	0	0	0	0	0	0	0	1	1	1	0	3	4	1	0	1	%0.50	
C44	Other Skin	92	0	0	0	0	0	1	1	3	1	10	8	15	17	13	8	6	8	%4.00	
C45	Mesothelioma	4	0	0	0	0	0	0	0	0	0	0	1	1	2	0	0	0	0	%0.20	
C46	Kaposi sarcoma	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	%0.10	
C47;C49	Connective,Soft tissue	60	1	1	0	2	0	0	2	8	5	8	6	5	8	4	4	4	3	%2.60	
C50	Breast	13	0	0	0	0	0	0	0	2	0	0	2	0	4	0	1	2	2	%0.60	
C60	Penis	2	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	%0.10	
C61	Prostate	173	0	0	0	0	0	0	0	1	0	1	3	14	21	33	33	39	26	%7.50	
C62	Testis	35	2	0	0	1	0	3	4	7	6	5	4	2	1	0	0	0	0	%1.50	
C63	Other male genital	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	%0.00	
C64	Kidney	99	3	2	1	0	0	0	1	4	11	11	15	13	9	14	10	2	5	%4.30	
C65	Renal Pelvis	4	1	0	0	0	0	0	0	0	0	0	1	0	2	0	0	0	0	%0.20	
C66	Ureter	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	%0.10	
C67	Bladder	112	1	0	0	0	0	0	1	5	11	8	10	12	8	16	18	10	11	%4.80	
C68	Other Urinary organs	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	%0.00	
C69	Eye	4	2	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	%0.20	
C70-C72	Brain, Nervous system	120	8	3	8	2	2	2	8	8	21	6	12	10	8	10	9	2	4	%5.20	
C73	Thyroid	80	0	0	0	0	0	1	4	6	17	14	9	8	11	2	6	1	1	%3.50	
C74	Adrenal gland	7	2	0	1	0	1	0	0	0	0	0	0	1	2	0	0	0	0	%0.30	
C75	Other Endocrine	2	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	%0.10	
C81	Hodgkin disease	85	0	1	2	5	7	6	11	12	8	11	2	5	5	4	4	1	2	%3.70	
C82-C85;C96	Non-Hodgkin lymphoma	140	4	3	2	7	6	5	8	7	15	13	17	12	13	16	5	5	3	%6.00	
C88	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%0.00	
C90	Multiple Myeloma	36	0	0	2	0	0	0	1	0	0	2	1	3	13	6	5	2	1	%1.60	
C91	Lymphoid Leukaemia	72	15	9	18	8	3	5	1	2	1	3	3	1	2	4	4	1	1	%3.10	
C92-C94	Myeloid Leukaemia	61	4	1	2	1	4	4	5	4	8	6	4	1	9	5	1	1	0	%2.60	
C95	Leukaemia unspec.	46	4	10	4	2	1	8	7	2	1	3	4	2	2	2	1	2	0	%2.00	
Other	Other & unspecified	58	5	1	4	2	0	2	3	1	5	5	8	7	1	8	6	0	1	%2.50	
		----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----
All	All sites Total	2316	55	35	46	40	30	45	87	118	177	192	215	247	274	285	208	163	121	%100.00	
Not C44	All sites but C44	2224	55	35	46	40	30	44	86	115	176	182	207	232	257	272	200	157	113	%96.00	

Table 5.4.2 Number Of Cases Among Non-Saudi Females by Primary Site And Age Groups, 2022

ICD (10th)	Site	All Ages	Age unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total (%)
C00	Lip	9	0	0	0	0	0	0	0	0	2	0	0	0	0	2	0	2	3	%60.40
C01-C02	Tongue	18	0	0	0	0	0	0	0	3	1	3	2	1	2	0	1	2	3	%60.70
C03-C06	Mouth	10	0	0	0	0	0	0	0	1	1	2	0	1	1	2	1	0	1	%60.40
C07-C08	Salivary glands	8	0	0	0	0	0	1	1	4	0	0	1	1	0	0	0	0	0	%60.30
C09	Tonsil	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	%60.00
C10	Other Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%60.00
C11	Nasopharynx	17	0	0	1	0	1	1	1	1	0	3	5	1	1	2	0	0	0	%60.70
C12-C13	Hypopharynx	2	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	%60.10
C14	Pharynx unspec.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%60.00
C15	Oesophagus	14	0	0	0	0	0	0	0	0	1	4	1	5	1	1	0	1	0	%60.60
C16	Stomach	48	0	0	0	0	0	0	0	3	0	8	6	4	5	6	7	5	4	%61.90
C17	Small intestine	6	0	0	0	0	0	0	1	0	2	0	0	0	1	0	0	0	2	%60.20
C18	Colon	141	1	0	0	1	0	1	2	4	15	13	22	17	16	19	11	7	12	%56.60
C19-C20	Rectum	58	1	0	0	0	0	1	4	2	5	4	8	10	5	9	4	4	1	%62.30
C21	Anus	2	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	%60.10
C22	Liver	38	0	0	2	1	0	0	0	0	0	1	4	2	7	6	6	4	5	%61.50
C23-C24	Gallbladder etc.	19	0	0	0	0	0	0	0	0	0	1	0	4	1	5	3	1	4	%60.80
C25	Pancreas	35	1	0	0	0	0	0	1	0	2	0	2	3	5	6	6	5	4	%61.40
C30-C31	Nose, sinuses etc.	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	%60.00
C32	Larynx	2	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	%60.10
C33-C34	Trachea,Bronchus,Lung	63	1	0	0	0	0	1	0	3	3	8	4	7	6	11	3	8	8	%62.50
C37-C38	Other Thoracic organs	6	0	1	0	0	0	0	0	1	3	0	0	0	0	0	0	0	1	%60.20
C40-C41	Bone	21	0	1	0	2	4	0	2	1	3	1	2	2	1	0	0	1	1	%60.80
C43	Melanoma of Skin	5	0	0	0	0	0	0	2	1	0	0	0	0	1	0	0	1	0	%60.20
C44	Other Skin	38	0	0	0	0	1	0	0	4	3	5	5	4	4	5	2	1	4	%61.50
C45	Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	%60.00
C46	Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%60.00
C47;C49	Connective,Soft tissue	36	0	2	0	5	0	2	5	2	4	1	7	1	1	2	1	2	1	%61.40
C50	Breast	1013	3	0	0	0	3	6	24	73	156	179	169	136	93	72	46	21	32	%40.20
C51	Vulva	7	0	0	0	0	0	0	0	1	2	0	0	0	2	1	1	0	0	%60.30
C52	Vagina	6	0	0	0	1	0	0	0	0	2	0	0	0	1	1	0	1	0	%60.20
C53	Cervix Uteri	68	1	0	0	0	0	0	2	9	10	12	7	7	5	7	3	4	1	%62.70
C54	Corpus Uteri	81	0	0	0	0	0	0	1	3	5	6	8	10	12	16	7	7	6	%63.20
C55	Uterus unspec.	33	0	0	0	0	0	0	0	1	5	3	1	3	3	8	3	3	3	%61.30
C56	Ovary	81	1	1	1	1	1	1	3	10	8	14	10	10	5	5	5	2	3	%63.20
C57	Other Female Genital	12	0	0	0	0	0	0	0	0	2	2	1	0	4	1	0	1	1	%60.50
C58	Placenta	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	%60.00
C64	Kidney	34	0	4	1	0	2	0	0	0	2	4	5	4	0	3	4	4	1	%61.30
C65	Renal Pelvis	2	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	%60.10
C66	Ureter	2	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	%60.10
C67	Bladder	23	0	0	0	0	0	1	0	0	1	0	4	4	2	3	5	2	1	%60.90
C68	Other Urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%60.00
C69	Eye	4	0	2	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	%60.20
C70-C72	Brain, Nervous system	62	0	4	3	6	0	3	3	3	5	6	6	7	6	5	1	3	1	%62.50
C73	Thyroid	195	1	0	0	0	2	7	15	26	44	33	27	20	10	5	3	2	0	%67.70
C74	Adrenal gland	6	0	2	1	1	0	0	0	1	0	1	0	0	0	0	0	0	0	%60.20
C75	Other Endocrine	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%60.00
C81	Hodgkin disease	44	0	0	1	3	3	4	5	5	5	5	4	0	2	1	2	2	2	%61.70
C82-C85;C96	Non-Hodgkin Lymphoma	82	0	0	0	1	2	3	5	4	7	14	10	8	5	7	9	2	5	%63.30
C88	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	%60.00
C90	Multiple Myeloma	18	0	0	0	0	0	0	1	2	0	1	2	0	5	4	3	0	0	%60.70
C91	Lymphoid Leukaemia	38	0	14	11	4	1	0	2	0	0	1	0	1	2	1	0	0	1	%61.50
C92-C94	Myeloid Leukaemia	33	1	3	0	1	2	1	3	0	4	4	1	5	2	3	0	2	1	%61.30
C95	Leukaemia unspec.	31	0	7	0	1	2	1	1	3	2	2	3	2	3	0	2	1	1	%61.20
Other	Other & unspecified	47	0	5	1	0	1	2	0	2	4	4	1	7	7	5	3	1	4	%61.90
		----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----
All	All sites Total	2523	11	46	23	28	25	38	87	174	313	346	329	289	228	225	142	102	117	%100.00
Not C44	All sites but C44	2485	11	46	23	28	24	38	87	170	310	341	324	285	224	220	140	101	113	%98.50

Table 5.4.3 Age-Specific Incidence Rate (AIR), Age Standardised Incidence Rate (ASR) Among Non-Saudi Males (per 100,000) by Primary Site and Age groups, 2022

ICD (10th)	Site	All Ages	Age unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World	
C00	Lip	14	0	0	0	0	0	0	0	0	0.2	0.1	0	0.8	0.5	0.5	2.4	0	0	0.1	0.2	
C01-C02	Tongue	34	0	0	0	0	0	0	0	0.1	0.3	0.2	0.6	0.5	1	1.4	5.9	8.6	8	0.3	0.7	
C03-C06	Mouth	17	0	0	0	0	0	0.1	0.1	0.1	0.1	0	0.5	0	0.3	1.4	1.2	5.7	0	0.2	0.3	
C07-C08	Salivary glands	17	0	0	0	0	0	0	0	0.1	0.1	0.1	0.4	0.2	0.8	1	1.2	2.9	4	0.2	0.3	
C09	Tonsil	2	0	0	0	0.4	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	
C10	Other Oropharynx	3	0	0	0	0	0	0	0	0	0	0	0.1	0.2	0	0.5	0	0	0	0	0	
C11	Nasopharynx	56	0	0	0	0.4	0	0.1	0.1	0.2	0.1	0.9	0.8	1.8	2	3.4	2.4	0	8	0.5	0.7	
C12-C13	Hypopharynx	2	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	1.2	0	0	0	0	
C14	Pharynx unspec.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C15	Oesophagus	20	0	0	0	0	0	0	0.1	0.1	0	0.1	0.1	0.8	0.5	1.9	2.4	5.7	0	0.2	0.3	
C16	Stomach	74	0	0	0	0	0	0	0.1	0.4	0.4	0.2	1.2	2.1	2.6	6.3	4.7	11.4	4	0.7	1.1	
C17	Small intestine	21	0	0	0	0	0	0	0	0	0	0.2	0.2	0.2	1.5	1.4	1.2	5.7	16.1	0.2	0.6	
C18	Colon	231	1	0	0	0	0	0.1	0.5	0.5	0.9	1.9	2.6	4.2	7.2	21.2	28.2	48.6	48.2	2.3	4.5	
C19-C20	Rectum	113	0	0	0	0	0	0	0.2	0.3	0.5	0.6	1.4	3.3	5.6	5.3	10.6	28.6	20.1	1.1	2.1	
C21	Anus	12	0	0	0	0	0	0	0	0	0.1	0.1	0.1	0.2	0.8	1	1.2	5.7	0	0.1	0.2	
C22	Liver	86	0	0	0	0	0	0	0.1	0.1	0.2	0.5	0.7	1.8	2.8	7.7	9.4	37.2	28.1	0.8	2.2	
C23-C24	Gallbladder etc.	17	0	0	0	0	0	0	0	0	0	0	0.5	0.5	0.8	1.4	0	11.4	0	0.2	0.4	
C25	Pancreas	55	1	0	0	0	0	0	0.1	0.1	0.2	0	0.7	0.7	1.8	4.3	12.9	17.1	20.1	0.5	1.5	
C30-C31	Nose, sinuses etc.	6	0	0	0	0	0	0	0	0.2	0	0.1	0.1	0	0	0	0	0	0	0.1	0	
C32	Larynx	22	0	0	0	0	0	0	0	0	0.1	0.1	0.5	0.5	1.3	0.5	2.4	5.7	8	0.2	0.5	
C33-C34	Trachea,Bronchus,Lung	118	0	0	0.4	0	0	0.1	0.2	0.2	0.2	0.6	0.8	3.4	4.1	7.2	16.5	45.7	36.1	1.2	2.9	
C37-C38	Other Thoracic organs	21	1	1	0	0	0.6	0.1	0.1	0.1	0.2	0.2	0.1	0.3	0	0.5	1.2	0	0	0.2	0.3	
C40-C41	Bone	52	1	0.5	0.4	3.5	2.9	0.4	0.2	0.2	0.2	0.5	0.7	0.3	0.3	1.4	3.5	0	0	0.5	1	
C43	Melanoma of Skin	12	0	0	0	0	0	0	0	0	0.1	0.1	0.1	0	0.8	1.9	1.2	0	4	0.1	0.2	
C44	Other Skin	92	1	0	0	0	0	0.1	0.1	0.2	0.1	0.8	0.9	2.4	4.3	6.3	9.4	17.1	32.1	0.9	2	
C45	Mesothelioma	4	0	0	0	0	0	0	0	0	0	0	0.1	0.2	0.5	0	0	0	0	0	0	
C46	Kaposi sarcoma	2	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	4	0	0.1	
C47;C49	Connective,Soft tissue	60	0	0.5	0	0.9	0	0	0.1	0.4	0.3	0.6	0.7	0.8	2	1.9	4.7	11.4	12	0.6	1.1	
C50	Breast	13	0	0	0	0	0	0	0	0.1	0	0	0.2	0	1	0	1.2	5.7	8	0.1	0.4	
C60	Penis	2	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0.5	0	0	0	0	0	
C61	Prostate	173	2	0	0	0	0	0	0	0.1	0	0.1	0.4	2.3	5.4	15.9	38.8	111.5	104.4	1.7	6.6	
C62	Testis	35	0	1	0	0.4	0	0.4	0.2	0.4	0.4	0.4	0.5	0.3	0.3	0	0	0	0	0.3	0.3	
C63	Other male genital	1	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	
C64	Kidney	99	0	1.4	0.4	0	0	0	0.1	0.2	0.7	0.9	1.8	2.1	2.3	6.7	11.8	5.7	20.1	1	1.8	
C65	Renal Pelvis	4	0	0.5	0	0	0	0	0	0	0	0	0.1	0	0.5	0	0	0	0	0	0.1	
C66	Ureter	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0.5	0	2.9	0	0	0.1	
C67	Bladder	112	1	0.5	0	0	0	0	0.1	0.3	0.7	0.6	1.2	2	2	7.7	21.2	28.6	44.2	1.1	2.8	
C68	Other Urinary organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0.3	0	0	0	0	0	0	
C69	Eye	4	0	1	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	4	0	0.2	
C70-C72	Brain, Nervous system	120	0	3.9	3.1	0.9	1.1	0.3	0.5	0.4	1.3	0.5	1.4	1.6	2	4.8	10.6	5.7	16.1	1.2	2.3	
C73	Thyroid	80	0	0	0	0	0	0.1	0.2	0.3	1	1.1	1.1	1.3	2.8	1	7.1	2.9	4	0.8	0.8	
C74	Adrenal gland	7	0	1	0.4	0	0.6	0	0	0	0	0	0	0.2	0.5	0	0	0	0	0.1	0.2	
C75	Other Endocrine	2	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	
C81	Hodgkin disease	85	0	0	0.8	2.2	4	0.9	0.7	0.6	0.5	0.9	0.2	0.8	1.3	1.9	4.7	2.9	8	0.8	1.4	
C82-C85;C96	Non-Hodgkin lymphoma	140	2	1.9	0.8	3.1	3.4	0.7	0.5	0.4	0.9	1	2	2	3.3	7.7	5.9	14.3	12	1.4	2.5	
C88	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C90	Multiple Myeloma	36	0	0	0.8	0	0	0	0.1	0	0	0.2	0.1	0.5	3.3	2.9	5.9	5.7	4	0.4	0.7	
C91	Lymphoid Leukaemia	72	0	7.2	7	3.5	1.7	0.7	0.1	0.1	0.1	0.2	0.4	0.2	0.5	1.9	4.7	2.9	4	0.7	2.5	
C92-C94	Myeloid Leukaemia	61	2	1.9	0.8	0.4	2.3	0.6	0.3	0.2	0.5	0.5	0.5	0.2	2.3	2.4	1.2	2.9	0	0.6	1	
C95	Leukaemia unspec.	46	1	1.9	1.5	0.9	0.6	1.1	0.4	0.1	0.1	0.2	0.5	0.3	0.5	1	1.2	5.7	0	0.4	0.9	
Other	Other & unspecified	58	0	2.4	1.5	0.9	0	0.3	0.2	0.1	0.3	0.4	0.9	1.1	0.3	3.9	7.1	0	4	0.6	1.2	
		----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----
All	All sites Total	2316	13	27	18	17	17	6	5	6	11	15	25	40	70	137	244	466	486	22.6	49.4	
Not C44	All sites but C44	2224	12	27	18	17	17	6	5	6	11	14	24	38	66	131	235	449	454	21.7	47.4	

Table 5.4.4 Age-Specific Incidence Rate (AIR), Age Standardised Incidence Rate (ASR) Among Non-Saudi Females (per 100,000) by Primary Site and Age groups, 202

ICD (10th)	Site	All Ages	Age unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World	
C00	Lip	9	0	0	0	0	0	0	0	0	0.5	0	0	0	0	4.1	0	13.6	18.8	0.3	0.8	
C01-C02	Tongue	18	0	0	0	0	0	0	0	0.6	0.2	1	1.1	0.8	2.7	0	3.8	13.6	18.8	0.6	1.1	
C03-C06	Mouth	10	0	0	0	0	0	0	0	0.2	0.2	0.7	0	0.8	1.3	4.1	3.8	0	6.3	0.3	0.6	
C07-C08	Salivary glands	8	0	0	0	0	0	0.5	0.3	0.8	0	0	0.5	0.8	0	0	0	0	0	0.3	0.2	
C09	Tonsil	1	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	0	0	
C10	Other Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C11	Nasopharynx	17	0	0	0.4	0	0.6	0.5	0.3	0.2	0	1	2.7	0.8	1.3	4.1	0	0	0	0.5	0.6	
C12-C13	Hypopharynx	2	0	0	0	0	0	0	0.3	0	0	0	0	0	0	2	0	0	0	0.1	0.1	
C14	Pharynx unspec.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C15	Oesophagus	14	0	0	0	0	0	0	0	0	0.2	1.4	0.5	4.2	1.3	2	0	6.8	0	0.4	0.6	
C16	Stomach	48	0	0	0	0	0	0	0	0.6	0	2.7	3.2	3.3	6.7	12.2	26.8	33.9	25.1	1.5	3.3	
C17	Small intestine	6	0	0	0	0	0	0	0.3	0	0.5	0	0	0	1.3	0	0	0	12.5	0.2	0.4	
C18	Colon	141	1	0	0	0.5	0	0.5	0.5	0.8	3.4	4.4	11.7	14.1	21.5	38.6	42	47.5	75.2	4.5	8.2	
C19-C20	Rectum	58	1	0	0	0	0	0.5	1	0.4	1.1	1.4	4.3	8.3	6.7	18.3	15.3	27.1	6.3	1.8	3.1	
C21	Anus	2	0	0	0	0	0	0	0	0	0.5	0	0	0	0	0	0	0	0	0.1	0	
C22	Liver	38	0	0	0.8	0.5	0	0	0	0	0	0.3	2.1	1.7	9.4	12.2	22.9	27.1	31.3	1.2	3.1	
C23-C24	Gallbladder etc.	19	0	0	0	0	0	0	0	0	0	0.3	0	3.3	1.3	10.2	11.5	6.8	25.1	0.6	1.6	
C25	Pancreas	35	1	0	0	0	0	0	0.3	0	0.5	0	1.1	2.5	6.7	12.2	22.9	33.9	25.1	1.1	2.9	
C30-C31	Nose, sinuses etc.	1	0	0	0	0	0	0	0.3	0	0	0	0	0	0	0	0	0	0	0	0	
C32	Larynx	2	0	0	0	0	0	0	0	0	0.2	0	0.5	0	0	0	0	0	0	0.1	0	
C33-C34	Trachea,Bronchus,Lung	63	1	0	0	0	0	0.5	0	0.6	0.7	2.7	2.1	5.8	8.1	22.4	11.5	54.3	50.1	2	4.4	
C37-C38	Other Thoracic organs	6	0	0.5	0	0	0	0	0	0.2	0.7	0	0	0	0	0	0	0	6.3	0.2	0.2	
C40-C41	Bone	21	0	0.5	0	0.9	2.4	0	0.5	0.2	0.7	0.3	1.1	1.7	1.3	0	0	6.8	6.3	0.7	0.9	
C43	Melanoma of Skin	5	0	0	0	0	0	0	0.5	0.2	0	0	0	0	1.3	0	0	6.8	0	0.2	0.2	
C44	Other Skin	38	0	0	0	0	0.6	0	0	0.8	0.7	1.7	2.7	3.3	5.4	10.2	7.6	6.8	25.1	1.2	2.1	
C45	Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0.8	0	0	0	0	0	0	0	
C46	Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C47;C49	Connective,Soft tissue	36	0	1	0	2.3	0	1	1.3	0.4	0.9	0.3	3.7	0.8	1.3	4.1	3.8	13.6	6.3	1.1	1.6	
C50	Breast	1013	3	0	0	0	1.8	3	6	14.8	35.6	60.5	90	112.9	125.2	146.3	175.8	142.4	200.5	32.3	41.7	
C51	Vulva	7	0	0	0	0	0	0	0	0.2	0.5	0	0	0	2.7	2	3.8	0	0	0.2	0.3	
C52	Vagina	6	0	0	0	0.5	0	0	0	0	0.5	0	0	0	1.3	2	0	6.8	0	0.2	0.3	
C53	Cervix Uteri	68	1	0	0	0	0	0	0.5	1.8	2.3	4.1	3.7	5.8	6.7	14.2	11.5	27.1	6.3	2.2	2.9	
C54	Corpus Uteri	81	0	0	0	0	0	0	0.3	0.6	1.1	2	4.3	8.3	16.2	32.5	26.8	47.5	37.6	2.6	5.4	
C55	Uterus unspec.	33	0	0	0	0	0	0	0	0.2	1.1	1	0.5	2.5	4	16.3	11.5	20.3	18.8	1.1	2.2	
C56	Ovary	81	1	0.5	0.4	0.5	0.6	0.5	0.8	2	1.8	4.7	5.3	8.3	6.7	10.2	19.1	13.6	18.8	2.6	3.5	
C57	Other Female Genital	12	0	0	0	0	0	0	0	0	0.5	0.7	0.5	0	5.4	2	0	6.8	6.3	0.4	0.7	
C58	Placenta	1	0	0	0	0	0	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0	
C64	Kidney	34	0	2	0.4	0	1.2	0	0	0	0.5	1.4	2.7	3.3	0	6.1	15.3	27.1	6.3	1.1	2.2	
C65	Renal Pelvis	2	0	0	0	0	0	0	0	0	0	0.3	0	0.8	0	0	0	0	0	0.1	0.1	
C66	Ureter	2	0	0	0	0	0	0	0	0	0.2	0	0	0	1.3	0	0	0	0	0.1	0.1	
C67	Bladder	23	0	0	0	0	0	0.5	0	0	0.2	0	2.1	3.3	2.7	6.1	19.1	13.6	6.3	0.7	1.7	
C68	Other Urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C69	Eye	4	0	1	0	0	0	0.5	0.3	0	0	0	0	0	0	0	0	0	0	0.1	0.2	
C70-C72	Brain, Nervous system	62	0	2	1.2	2.8	0	1.5	0.8	0.6	1.1	2	3.2	5.8	8.1	10.2	3.8	20.3	6.3	2	2.9	
C73	Thyroid	195	1	0	0	0	1.2	3.5	3.8	5.3	10	11.2	14.4	16.6	13.5	10.2	11.5	13.6	0	6.2	5.6	
C74	Adrenal gland	6	0	1	0.4	0.5	0	0	0	0.2	0	0.3	0	0	0	0	0	0	0	0.2	0.2	
C75	Other Endocrine	1	0	0	0.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C81	Hodgkin disease	44	0	0	0.4	1.4	1.8	2	1.3	1	1.1	1.7	2.1	0	2.7	2	7.6	13.6	12.5	1.4	1.9	
C82-C85;C96	Non-Hodgkin lymphoma	82	0	0	0	0.5	1.2	1.5	1.3	0.8	1.6	4.7	5.3	6.6	6.7	14.2	34.4	13.6	31.3	2.6	4.2	
C88	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C90	Multiple Myeloma	18	0	0	0	0	0	0	0.3	0.4	0	0.3	1.1	0	6.7	8.1	11.5	0	0	0.6	1.1	
C91	Lymphoid Leukaemia	38	0	7.1	4.5	1.8	0.6	0	0.5	0	0	0.3	0	0.8	2.7	2	0	0	6.3	1.2	1.9	
C92-C94	Myeloid Leukaemia	33	1	1.5	0	0.5	1.2	0.5	0.8	0	0.9	1.4	0.5	4.2	2.7	6.1	0	13.6	6.3	1.1	1.6	
C95	Leukaemia unspec.	31	0	3.6	0	0.5	1.2	0.5	0.3	0.6	0.5	0.7	1.6	1.7	4	0	7.6	6.8	6.3	1	1.6	
Other	Other & unspecified	47	0	2.5	0.4	0	0.6	1	0	0.4	0.9	1.4	0.5	5.8	9.4	10.2	11.5	6.8	25.1	1.5	2.7	
		----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----
All	All sites Total	2523	11	23	9	13	15	19	22	35	71	117	175	240	307	457	543	692	733	80.4	121.4	
Not C44	All sites but C44	2485	11	23	9	13	15	19	22	35	71	115	173	237	302	447	535	685	708	79.2	119.3	

ACKNOWLEDGEMENT

We would like to express our deepest gratitude to the following champions for their invaluable contribution and support for the 2022 Report.

Based on Alphabetical order

1- Asser Central Hospital:

Mr. Ibrahim saeed Algamdi
Eng. Mohammed Meateqal Qahtani
Eng. Marwan Mohammed Abu Ali

2- Abu Arish general hospital:

Mr. Mohammed Hussain Ayashi

3- Armed forces Hospital Riyadh:

Dr. Esam Murshid
Ms. Njoud Alshahrani

4- Armed Forces Hospital Southern region:

Mr. Ali Saeed Almarri
Mr. Amer Mohammed Alshehri

5- Almana general hospital Eastern region:

Mr. Khaled Abdulhady Ali
Ms. Amnah Jafer Aljishi
Ms. Maryem Ahmed Albuayjan

6- Alhada Armed Forces Hospital:

Ms. Marifah Abdullah Khawjah

7- Care National Hospital:

Mr. Manea Saleh Alyami

8- Dammam Medical Complex:

Dr. Mohammed Dhafir AlAhmari
Mr. Ahmed Abdullah Masood
Ms. Alaa Fathi Al.Habib
Ms. Khatoon Hussain Al.Bahrani

9- Dr. Sulaiman Al Habib Group:

Dr. Mehwish Ateeq
Ms. Alaa Abdulaziz BinAyeed
Ms. Loreta Umlas Zapanta
Ms. Nora Casuga Ramos
Ms. Cristine Faye Rojo Tacan
Ms. Haya Abdulrahman Al Dawood

Ms. Ahood Nasser Abdullah Alsaig

Mr. Ghalib AlDarbi

Ms. Essra Salah Aldeen Alkhalifa

Ms. Nora Casuga Ramos

Ms. Cristine Faye Rojo Tacan

Ms. Haya Abdulrahman Al Dawood

10- International medical center hospital:

Ms. Rema Alhebshi

Ms. Elham Alsulami

11- Jazan Regional Health Laboratory:

Mr. Mohammed Abdu Muqarbish

12- Johns Hopkins Aramco Healthcare:

Ms. Maram AlAbbad

Ms. Munirah AlQahtani

Ms. Amal AlShehri

Ms. Anne Walters

13- King Abdulaziz Medical City for National guard in Riyadh:

Mr. Abd Rahman Albiaby

Mr. Sultan Bin Taleb

14- King Abdulaziz Medical City for National guard in Jeddah:

Dr. Mubarak Almansour

15- King Abdulaziz university hospital:

Dr. Shadi Alkhayatt

16- King Abdullah medical city:

Dr. Hussein Elsayed

Ms. Asmaa Saeed Almadani

17- King Fahad Medical City:

Dr. Abdullah Al.Sharm
Dr. Mohammed Marei
Dr. Muhammad Nasir Khan
Mr. Awadh Saleh Alamri
Ms. Noura Alanzi
Ms. Thekra Bin Shouil
Mr. Abdullah Alanazi
Ms. Nouf Alquhtani
Ms. Amani Aljaber

18- King Saud University hospital:

Dr. Mohammed Alghamdi
Ms. Maram Alharbi

19- King Fahad armed forces hospital:

Dr. Eman Alhazmi
Dr. Sara Altayyb
Dr. Ehab Taha
Dr. Waleed Alsyyad
Dr. Semsem Mushtaq
Dr. Bahaa Allethi
Mr. Rayan Althobaity

20- King Fahad Specialist Hospital, Tabuk:

Ms. Khadija Yahya Alkaabi

21- King Fahad Hospital, Hofuf:

Dr. Ibraheem Khalifa Al. Hanoot
Dr. Hisham Abdulrahman Al.Eissa
Mrs. Jawaher Ahmed Al.Hemaid
Mrs. Abrar Mohammed Al.Hamad
Mr. Maytham Taqi Al.Haddad
Mr. Mohammed Abdulwahab Al.Aithan
Mr. Ibrahim Mohammed Al.Habib
Mr. Omar Muhanna Al.Muhani
Mr. Habeeb Hussain Al.Jubran
Dr. Jawad Hussain Al.Khalaf
Mr. Habib Khalifa Binkhalaf

22- Prince Faisal bin Bandar Center, King Fahd Specialist Hospital, Buraidah:

Mr. Mohsen Abdellatif Gadelhak

23- King Khalid General Hospital, Hail:

Mr. Ammar mohammed Almithen

24- King Abdulaziz Specialist Hospital, Al.Jouf:

Mr. Ahmed abu el gasim Abdelrahman dafaalla

25- Kingdom Hospital:

Roselle Taruc Tagao
Lito Bergonzado

26- King Khaled Eye Specialist Hospital:

Ms. Reem Abdullah AlKhodair

27- King Khalid General Hospital, Hail:

Mr. Ahmed Awadh Alanazi

28- King Fahad Central Hospital, Jazan:

Mr. Ahassan Mohd Hussin Ashwi
Mr. Dinesh Chengalil

29- King Fahad Specialist hospital in Dammam:

Dr. Mohammed Rahal
Ms. Aisha Alsowayigh
Ms. Arwa Alswailem
Ms. Fatima Almulhim
Ms. Norah AlDossari
Ms. Munirah Alqahtani

30- King Fahad Hospital of the University:

Prof. Dr. Mohammed AlShahrani
Prof. Dr. Ali AlAmri
Ms. Kholoud Allkhwani.
Ms. Abrar AlFarid

31- King Faisal Specialist Hospital & Research Centre in Riyadh:

Dr. Shouki Bazarbashi
Ms. Doha Fatani
Ms. Salma Aljared
Mr. Mohamed Alammari

Mr. Abdul Rasim Thurakkal
Ms. Rehab Alsawi
Mr. Faisal Alanazi

32- King Faisal Specialist Hospital & Research Centre in Jeddah:

Ms. Laila Banjar
Mr. Majed Naser
Ms. Rawan Hariri
Mr. Adel Alamari

33- King Saud Medical City (KSMC):

Dr. Mohammed Almashyakhi
Mr. Nabeel Khalil Gohoum

34- Maternity and Children Hospital Dammam:

Dr. Bassam Alhejili
Dr. Fatimah Alyousef
Dr. Sukinah Al.Talaq
Ms. Dalia Ali Alouf
Ms. Fatimah Al.Khazal
Ms. Alaa Redah Alhargan
Ms. Amal Roudh Alshaalan
Ms. Maryam Ahmed Almeshkhas

35- Mouwasat Hospital:

Dr. Khalid Qassam GHallab
Dr. Hebatallah Madkour
Ms. Prajeesha Pakkarath
Ms. Marwa Almassari
Ms. Noura Alrammah
Ms. Reem A. Alshmmari
Ms. Reem Alyami

36- Prince Mohammed Bin Nasser Hospital, Jazan:

Mr. Essa Hassan Jeffery

37- Specialized Medical Center hospital in Riyadh:

Dr. Hasan Masoud
Ms. Nazeek Abdelaziz
Ms. Melyn Escobar

38- Prince Sultan Oncology Center, King Salman Armed Forces Hospital, Tabuk:

Mr. Osama Mukhtar

39- Saudi German Hospital – Aseer:

Mr. Mohammed Qasim
Ms. Amjad Mesfer Alshehri

40- Samtah General hospital:

Mr. Ahmed Ghalfan Hantool

41- Sabya General Hospital:

Mr. Abdulrhman eissa Meary

42- Security Forces Hospital Makkah:

Mr. Abdulaziz obied Alwuthaynani
Ms. Hatoon Mohammed Badawood

43- Security Forces Hospital Riyadh:

Ms. Alyah Alenazi

44- Al Hammadi Al Hospitals:

Dr. Emad Bukhari



ARABIC SUMMARY



السرطانات العشرة الأكثر شيوعاً بين السعوديين لكلا الجنسين:

احتل سرطان الثدي المرتبة الأولى (٣٣٣٤ حالة) بنسبة ١٧,٣٪ تلاه سرطان القولون والمستقيم (٢٥٣٥ حالة) بنسبة ١٣,٢٪ ثم سرطان الغدة الدرقية (١٦٧٧ حالة) بنسبة ٨,٧٪ ثم السرطان اللمفاوي اللاهودجكن (١٠٩٨ حالة) بنسبة ٥,٧٪ ثم سرطان ابيضاض الدم (٨٩٢ حالة) بنسبة ٤,٦٪، يليه سرطان البروستاتا (٦٦١ حالة) بنسبة ٣,٤٪ ثم سرطان الكبد (٦٥٠ حالة) بنسبة ٣,٤٪ يليه سرطان الجهاز العصبي والدماغ (٦٥٠ حالة) بنسبة ٣,٤٪ ثم سرطان الرحم (٦٤٧ حالة) بنسبة ٣,٤٪ وأخيراً سرطان الكلى (٦٣٠ حالة) بنسبة ٣,٣٪.

السرطانات العشرة الأكثر شيوعاً بين السعوديين لكلا الجنسين:

الذكور	الذكور	الذكور	الذكور	الإناث	الإناث
٨٧٤٨	٪	١٠٤٨٥	٪	٨٧٤٨	٪
١٦٨	١٤٧٠	القولون والمستقيم	٣١,٣	٣٢٨٠	الثدي
٧,٦	٦٦١	البروستاتا	١٢,٣	١٢٨٨	الغدة الدرقية
٧,٢	٦٢٧	اللمفاوي اللاهودجكن	١٠,٢	١٠٦٥	القولون والمستقيم
٥,٩	٥١٧	ابيضاض الدم	٦,٢	٦٤٧	الرحم
٥,٤	٤٧٤	المثانة	٤,٥	٤٧١	اللمفاوي اللاهودجكن
٥,٣	٤٦٤	الرئة	٣,٦	٣٧٥	ابيضاض الدم
٥,٠	٤٣٧	الكبد	٢,٩	٣٠٠	المبيض
٤,٦	٤٠٥	الكلية	٢,٧	٢٨٣	الجهاز العصبي والدماغ
٤,٤	٣٨٩	الغدة الدرقية	٢,١	٢٢٥	الكلى
٤,٢	٣٦٧	الجهاز العصبي والدماغ	٢,٠	٢١٣	الكبد

السرطانات العشرة الأكثر شيوعاً بين الأطفال السعوديين لكلا الجنسين:

احتل سرطان ابيضاض الدم المرتبة الأولى (٢٧١ حالة) بنسبة ٣١,٧٪ تلاه سرطان الجهاز العصبي (١٥٥ حالة) بنسبة ١٨,١٪ ثم السرطان اللمفاوي هودجكن (٦٩ حالة) بنسبة ٨,١٪ ثم سرطان العظام (٦٥ حالة) بنسبة ٧,٦٪ ثم سرطان اللمفاوي اللاهودجكن (٥٨ حالة) بنسبة ٦,٨٪، يليه سرطان الكلى (٤٧ حالة) بنسبة ٥,٥٪، ثم سرطان الأنسجة الضامة والرخوة (٣٧ حالة) بنسبة ٤,٣٪، ثم سرطان العين (٢٦ حالة) بنسبة ٣٪، ثم سرطان الغدة الكظرية (٢٤ حالة) بنسبة ٢,٨٪، وأخيراً سرطان الغدة الدرقية (١٣ حالة) بنسبة ١,٥٪.

السرطانات العشرة الأكثر شيوعاً بين الأطفال السعوديين لكلا الجنسين:

الذكور	الذكور	الذكور	الذكور	الإناث	الإناث
٤٦٨	٪	٣٨٧	٪	٤٦٨	٪
٣٢,٣	١٥١	ابيضاض الدم	٣١,٠	١٢٠	ابيضاض الدم
١٦,٩	٧٩	الجهاز العصبي والدماغ	١٩,٦	٧٦	الجهاز العصبي والدماغ
١٠,٧	٥٠	اللمفاوي هودجكن	٩,٠	٣٥	العظام
٧,٧	٣٦	اللمفاوي اللاهودجكن	٧,٢	٢٨	الكلى
٦,٤	٣٠	العظام	٥,٧	٢٢	اللمفاوي اللاهودجكن
٤,٣	٢٠	الأنسجة الضامة والرخوة	٤,٩	١٩	اللمفاوي هودجكن
٤,١	١٩	الكلى	٤,٤	١٧	الأنسجة الضامة والرخوة
٣,٤	١٦	العين	٢,٨	١١	الغدة الكظرية
٢,٨	١٣	الغدة الكظرية	٢,٦	١٠	العين
١,١	٥	الخصية	٢,٦	١٠	الغدة الدرقية

إحصائيات السرطان في المملكة العربية السعودية لعام ٢٠٢٢

السجل السعودي للأورام

أنشئ السجل السعودي للأورام في عام ١٤١٢ هـ (١٩٩٢م) بدأ السجل نشاطه في جمع المعلومات من شهر يناير في عام ١٩٩٤ م، حيث يتم جمع وترميز البيانات وتدخل حسب النظام المعتمد من منظمة الصحة العالمية وتحلل البيانات بشكل دوري. يقوم السجل بتزويد الجهات المختصة والباحثين بمعلومات إحصائية وفق نموذج خاص على صفحة السجل في الموقع الرسمي للمجلس الصحي السعودي:

[HTTPS://SHC.GOV.SA/ARABIC/NCC/ACTIVITIES/PAGES/ANNUALREPORTS.ASPX](https://shc.gov.sa/arabic/ncc/activities/pages/annualreports.aspx)

إحصائيات السرطان لعام ٢٠٢٢

بلغ إجمالي عدد حالات السرطان المكتشفة في عام ٢٠٢٢ والمسجلة من مختلف المرافق الصحية الحكومية والخاصة بالمملكة العربية السعودية ٢٤٠٧٢ حالة، من بين هذه الحالات ١٩٢٣٣ سعوديين بنسبة ٧٩,٩٪ وغير سعوديين ٤٨٣٩ بنسبة ٢٠,١٪. وكان عدد حالات السرطان لدى السعوديين الذكور ٨٧٤٨ حالة بنسبة أجمالية قدرها ٤٥,٤٨٪ بينما بلغ عدد الحالات لدى الإناث السعوديات ١٠٤٨٥ حالة بنسبة إجمالية قدرها ٥٤,٥٢٪.

غير سعوديين			سعوديون			المجموع الكلي
المجموع	أنثى	ذكر	المجموع	أنثى	ذكر	٢٤٠٧٢
٤٨٣٩	٢٥٢٣	٢٣١٦	١٩٢٣٣	١٠٤٨٥	٨٧٤٨	

بلغ المعدل المعياري للإصابة بالسرطان بين الرجال ١٤٤,٩ حالة لكل ١٠٠٠٠٠ نسمة، وبين النساء ١٥٩,١ حالة لكل ١٠٠٠٠٠ نسمة.

الملخص العربي
تقرير معدل الإصابة لمرض السرطان
المملكة العربية السعودية
٢٠٢٢

الحمد لله والصلاة والسلام على رسول الله وعلى آله وصحبه ومن والاه، أما بعد:

يُضطلع السجل السعودي للأورام بالمركز الوطني للسرطان بالمجلس الصحي السعودي بجمع وتبويب وتحليل بيانات حالات السرطان في المملكة العربية السعودية للعام ٢٠٢٢م والتأكد من سلامتها، وذلك بمشاركة من جميع القطاعات الصحية الحكومية والأهلية في المملكة.

ويحرص المركز الوطني للسرطان على تقديم الدعم الإداري والفني للسجل لأداء مهامه بفعالية، والاستفادة من الإحصائيات المتراكمة في وضع أولويات مكافحة السرطان وعلاجه ووضع البرامج

الوطنية المناسبة في هذا الشأن، وتطوير وتحسين مستويات الرعاية الصحية المقدمة لمرضى السرطان.

أسعد بتقديم جزيل الشكر إلى الفريق الفني القائم على إعداد وتنفيذ هذا التقرير من الزملاء والزميلات بالمركز الوطني للسرطان ومسجلي السرطان في كافة القطاعات الصحية على جهودهم المبذولة في إنجاز هذا العمل الكبير، والشكر موصول إلى جميع أعضاء اللجنة العلمية للسرطان وللمراجعين هذا التقرير على ما قدموه من جهود ملموسة في السجل الوطني للأورام، بما يخدم القطاع الصحي.

أ.د. مشيب بن علي العسيري

مدير عام المركز الوطني للسرطان



بسم الله الرحمن الرحيم

الحمد لله رب العالمين، والصلاة والسلام على أشرف خلق الله محمد بن عبد الله وعلى آله وصحبه ومن وآله إلى يوم الدين، وبعد:



يحتوي التقرير السنوي لأعمال السجل السعودي للأورام لعام ٢٠٢٢م، الذي يقدمه المجلس الصحي السعودي ممثلًا في المركز الوطني للسرطان؛ على إنجازات السجل وأنشطته وبرامجه التي قام بها مؤخرًا، حيث تدعم التقارير التي يصدرها السجل الجهود المبذولة في مجال مكافحة السرطان، وتزوّد القائمين على المشاريع العلاجية والوقائية بالبيانات التفصيلية الدقيقة للسرطان؛ والتي تشخّص الوضع الحقيقي لحالات السرطان في المملكة، وتحدد أكثر أنواعه شيوعاً حسب النوع والعمر والموقع الجغرافي.

كما تتيح تقارير السجل لأصحاب القرار، التخطيط لاستحداث مراكز لعلاج مرض السرطان والتصدي له، وكذلك برامج التثقيف الصحي للوقاية منه، تماشياً مع الاستراتيجيات الوطنية والأهداف الصحية التي أعدها المجلس الصحي السعودي، المتضمنة التنسيق والتكامل بين الجهات المعنية بالصحة؛ لتحسين وتعزيز الرعاية الصحية؛ وفق رؤية المملكة ٢٠٣٠، لتحقيق تطلعات القيادة الحكيمة والمواطنين والمقيمين.

إن ما يشهده القطاع الصحي في وطننا الغالي من تطور ملموس ومشاهد؛ جاء أولاً بفضل من الله تعالى ثم بدعم حكومتنا الرشيدة بقيادة خادم الحرمين الشريفين وسمو ولي عهده الأمين -حفظهما الله، ومتابعة معالي رئيس المجلس الصحي السعودي وأعضاء المجلس، ولا يفوتني في هذا المقام أن أقدم الشكر الجزيل إلى الزملاء والزميلات في المجلس الصحي السعودي ممثلًا بالمركز الوطني للسرطان على عملهم الدؤوب وجهدهم المستمر الذي قاموا به لإعداد هذا التقرير وتحقيق رسالة السجل وأهدافه لتسجيل حالات السرطان في كافة مناطق المملكة، والشكر موصول إلى كافة منسوبي القطاع الصحي والهيئات والمؤسسات والجمعيات الخيرية الذين أولوا مرضى السرطان عناية كبيرة وقاموا بإعداد البرامج العلاجية والتوعوية للوقاية من هذا المرض.

د. نهار بن مزكي العازمي

الأمين العام للمجلس الصحي السعودي

تقرير
معدل الإصابة
بمرض السرطان
2022



المجلس الطبي السعودي
Saudi Health Council



المجلس الصحي السعودي
Saudi Health Council

المملكة العربية السعودية
المجلس الصحي السعودي
المركز الوطني للسرطان
السجل السعودي للأورام

تقرير
معدل الإصابة
بمرض السرطان
2022